



# Solvency & Financial Condition Report 2024

Assurant Europe Insurance N.V.



ASSURANT®

# Contents

|   |    |
|---|----|
| Executive Summary .....   | 1  |
| A Business and performance.....   | 3  |
| A.1 Business.....   | 3  |
| A.2 Underwriting Performance .....  | 5  |
| A.3 Investment Performance .....  | 6  |
| A.4 Performance of other activities .....                                       | 7  |
| B System of governance.....   | 8  |
| B.1 General information on the system of governance.....                        | 8  |
| B.2 Fit and proper requirements.....  | 11 |
| B.3 Risk management system including the own risk and solvency assessment ..... | 11 |
| B.4 Internal control system .....   | 13 |
| B.5 Internal audit function .....   | 14 |
| B.6 Actuarial function.....   | 15 |
| B.7 Outsourcing.....  | 15 |
| B.8 Any other disclosures .....   | 16 |
| C Risk management.....  | 17 |
| C.1 Underwriting risk.....  | 17 |
| C.2 Market risk .....   | 21 |
| C.3 Credit risk .....   | 23 |
| C.4 Liquidity risk .....  | 24 |
| C.5 Operational risk.....   | 26 |
| C.6 Other material risks.....   | 26 |
| C.7 Any other disclosures .....   | 27 |
| D Valuation for Solvency purposes .....   | 28 |
| D.1 Assets .....  | 28 |
| D.2 Technical provisions.....   | 31 |
| D.3 Other liabilities.....  | 34 |
| D.4 Alternative methods for valuation.....                                      | 35 |
| D.5 Any other disclosures.....  | 35 |
| E Capital management .....  | 36 |
| E.1 Own funds .....   | 36 |
| E.2 Solvency Capital Requirement and Minimum Capital Requirement .....          | 38 |

|   |    |
|---|----|
| E.3 Use of the duration-based equity risk sub-module in the calculation of the Solvency Capital Requirement .....                 | 38 |
| E.4 Differences between the standard formula and any internal models used .....   | 39 |
| E.5 Non-compliance with the minimum capital requirement and significant non-compliance with the solvency capital requirement..... | 39 |
| E.6 Any other disclosures .....   | 39 |
| F Quantitative reporting templates .....  | 40 |

## Executive Summary

Assurant Europe Insurance N.V. (further referred to as “AEI” or “the company”), is a Non-Life insurance company, incorporated in the Netherlands as a Naamloze Vennootschap (public limited company) on 29 October 2018. It received its license to operate on 9 June 2020. AEI is supervised by De Nederlandsche Bank (“DNB”) and the Autoriteit Financiële Markten (“AFM”).

This report has been prepared to comply with the reporting requirements of the EU-wide regulatory framework for insurance companies, Solvency 2, which came into force 1 January 2016.

### Business and performance

AEI engages in the following three segments of insurance:

- Connected Living - comprising the insurance of electronic devices for extended warranty, theft and accidental damage. The most important product is that of the insurance of mobile phones.
- Auto - comprising extended warranty and ancillary insurances that are tied to a vehicle; and
- Creditor - comprising disability, unemployment, accident, and life. This segment went into run-off in 2018 and no new policies were written since.

These are primarily consumer insurance products that are sold in the European Union through freedom of service arrangements and distributed on a Business-to-Business-to-Consumer basis, via relationships with vehicle importers/dealers, manufacturers, retailers, and other distributors.

AEI closed 2024 with a statutory profit after tax of Euro 8.1m. This comprised an operational pre-tax profit of Euro 6.2m and investment income of Euro 4.5m.

Section A provides an overview of business performance in the year under review.

### System of governance

AEI is governed by a two-tier board structure with a Board of Directors and a Supervisory Board of Directors. AEI implemented the governance requirements of the Solvency 2 regime and has four key functions: actuarial, compliance, risk management and internal audit.

Refer to section B for further details.

### Risk profile

As a provider of Non-Life and Health (income protection) insurance as well as some ancillary services, the company is exposed to a number of risks, the main ones being Underwriting risk and Market risk. The company invests substantial amounts in fixed income instruments and is exposed to market volatility and default risk, both for which appropriate amounts of solvency capital are set aside. In addition, existing and emerging regulation poses operational risks, which, whilst not necessarily having a very large financial impact, could impede the company’s medium-term outlook for doing business when not properly addressed.

Section C demonstrates in further detail to which risks the company is exposed and how these risks are mitigated.

## Valuation for solvency purposes

This SFCR provides insight in the company's balance sheet and available capital prepared in accordance with Solvency 2 guidelines. These guidelines strive for a market consistent valuation. In comparison to the statutory financial statements (BW2 Titel 9), Solvency 2 portrays a current and economic view on shareholder value and liabilities to policyholders. Under Dutch GAAP many items, such as policyholder liabilities, are valued at historical cost and gains are recognised over the lifetime of products.

Chapter D explains the differences between Solvency 2 and statutory valuation in more detail.

## Capital management

The company's capital management focusses on facilitating the acceptance of new business and the orderly run-off of its Creditor portfolio. The company's solvency position is above average for a Non-Life carrier, which is intended given anticipated growth. The year-end solvency position is as follows:

|                         | 2024        | 2023        |
|-------------------------|-------------|-------------|
| €'000                   |             |             |
| Eligible Own Funds      | 89,040      | 99,787      |
| SCR                     | 42,164      | 41,534      |
| <b>Solvency Ratio %</b> | <b>211%</b> | <b>240%</b> |

The SCR remained stable, in line with business volumes, whereas Own funds decreased by Euro 11m as a consequence of paying dividends of Euro 25m and accretion of business value that was underwritten in 2024 and earlier.

Further detail is provided in Section E.

## Outlook

The outlook for 2025 is fairly stable in spite of macro-economic uncertainties in relation to heightened inflation, driven by geopolitical uncertainty and the consequences of the change in US administration that drove the implementation of import tariffs in different jurisdictions.

AEI's products often but not always provide fixed claim payment for a loss event and are therefore only partially impacted by (sustained) inflation. AEI's expense provisions are considered sufficiently robust but it should be recognised that a prolonged period of higher than usual inflation would impact the company at some point in time.

The above increases the potential volatility of future outcomes to above what we have seen in the past decade and the level of volatility of future economic outcomes may be higher than historical developments would indicate.

# A Business and performance

## A.1 Business

### A.1.1 Name and legal form

AEI is a Non-Life insurance company based in Amsterdam, the Netherlands. The company was incorporated on 29 October 2018 and received its license to operate as a Non-Life insurer on 9 June 2020. It is a Naamloze Vennootschap.

### A.1.2 Name and contact details of the responsible supervisory authorities

Prudential supervision of AEI is the responsibility of De Nederlandsche Bank (“DNB”), Westeinde 1, 1000 AB, Amsterdam, The Netherlands.

Financial conduct is supervised by the Autoriteit Financiële Markten (“AFM”), Vijzelgracht 50, 1017 HS, Amsterdam, The Netherlands.


### A.1.3 Name and contact details of external auditor

AEI’s external auditor is Deloitte Accountants B.V., Gustav Mahlerlaan 2970, 1081 LA, Amsterdam, The Netherlands.

### A.1.4 Shareholders and position within the group

AEI’s shares are held by TWG Europe Ltd, one of the holding companies ultimately owned by Assurant Inc, a public company listed on the New York Stock Exchange (ticker: AIZ), registered in Delaware, United States of America.

A simplified version of the group’s corporate structure is shown below.



- Notes:**
1. TWGE Group refers to TWG Europe Limited and its subsidiaries (direct and indirect).
  2. All depicted entities are 100% owned by their immediate shareholder (shown by blue connecting lines) except for Assurant, Inc. which is publicly listed.
  3. This chart does not show intermediary holding companies above TWGE.

AEI has issued 43,600,001 shares which are owned by TWG Europe Ltd.

### A.1.5 Material lines of business and material geographical areas where business is carried out

AEI's principal activity is the underwriting of Non-Life insurance risk in the European Union. Its main clients are larger Mobile phone operators, Mobile phone distributors, Automotive industry manufacturers or distributors/dealers and (online) retailers.

AEI distinguishes the following segments:

- Connected Living (insurance of electronic devices including mobile phones)
- Auto (provision of extended warranty periods)
- Creditor (disability, unemployment). This segment is in run-off since 2018.

Its Solvency 2 lines of business are:

- Fire and Other Property Damage
- Income Protection (Health SLT)
- Miscellaneous Financial Loss

The material lines of business are illustrated in the table below, using financial information for the year ended 31 December 2024.

| €'000                          | Technical Provisions<br>(excl. risk margin) |              |              | Premiums earned |               |                |
|--------------------------------|---|--------------|--------------|-----------------|---------------|----------------|
|                                | Gross                                       | Ceded        | Net          | Gross           | Ceded         | Net            |
| Fire and other property damage | 10,149                                      | 3,680        | 6,469        | 193,349         | 86,552        | 106,798        |
| Health SLT                     | -13,888                                     | 10           | -13,898      | 5,933           | 101           | 5,832          |
| Miscellaneous financial loss   | 12,432                                      | 1,104        | 11,328       | 24,155          | 2,625         | 21,529         |
| <b>Total</b>                   | <b>8,693</b>                                | <b>4,794</b> | <b>3,899</b> | <b>223,437</b>  | <b>89,278</b> | <b>134,159</b> |

The four largest territories of operation are Spain, France, Italy, Hungary and Germany.

### A.1.6 Significant business or other events that have occurred during the reporting period

The following events had a significant impact on the company:

#### Interest rate environment

In the course of 2024, market interest rates in the European Union reduced, when to a lesser extent than in 2023, driving up investment income for the company.

#### Inflation

The level of inflation remained above the European Central Bank's desired long term average. This had a negative impact on the company's technical result as on some programs cost per claim and claims handling costs increased.

### A.1.7 Business performance

Whilst this report generally provides information that is based on valuation rules required by the Solvency 2 reporting regime, the sections A.2, A.3 and A.4 are required to be reported in accordance with the measurement basis as shown in the company's financial statements, which in AEI's case, is Dutch GAAP (BW2, Titel 9). The disclosure rules of Solvency 2 do require the business performance of the company to be analysed using three distinct sections, being:

- Underwriting performance
- Investment performance
- Performance of other activities

The table below shows the performance of the company's operations by section.

|  |             | 2024          | 2023          |
|--|-------------|---------------|---------------|
| €'000  |             |               |               |
| Underwriting performance                                   | Section A.2 | 6,159         | 3,651         |
| Investment performance                                     | Section A.3 | 4,462         | 8,238         |
| Performance of other activities                            | Section A.4 | -             | -             |
| <b>Profit before tax in statutory financial statements</b> |             | <b>10,621</b> | <b>11,888</b> |

## A.2 Underwriting Performance

Underwriting performance per Solvency 2 line of business is summarised in the following table.

|   | Fire & Other<br>Damage to<br>Property | Miscellaneous<br>Financial<br>Loss | Health<br>(SLT) | Total        |
|---|---------------------------------------|------------------------------------|-----------------|--------------|
| €'000   |                                       |                                    |                 |              |
| <b>Premiums written</b>                                   |                                       |                                    |                 |              |
| Gross - Direct Business                                   | 212,646                               | 17,123                             | 5,890           | 235,659      |
| Reinsurers' share   | 89,435                                | 737                                | 96              | 90,267       |
| Net   | 123,211                               | 16,386                             | 5,794           | 145,392      |
| <b>Premiums earned</b>                                    |                                       |                                    |                 |              |
| Gross - Direct Business                                   | 193,349                               | 24,155                             | 5,933           | 223,437      |
| Reinsurers' share   | 86,552                                | 2,625                              | 101             | 89,278       |
| Net   | 106,798                               | 21,529                             | 5,832           | 134,159      |
| <b>Claims incurred</b>                                    |                                       |                                    |                 |              |
| Gross - Direct Business                                   | 42,056                                | 3,452                              | 780             | 46,287       |
| Reinsurers' share   | 19,861                                | 704                                | 12              | 20,577       |
| Net   | 22,194                                | 2,748                              | 768             | 25,710       |
| <b>Expenses incurred</b>                                  |                                       |                                    |                 |              |
| Other expenses  | 83,129                                | 16,425                             | 2,735           | 102,289      |
| Total expenses  |                                       |                                    |                 | 102,289      |
| <b>Underwriting result</b>                                | <b>1,474</b>                          | <b>2,356</b>                       | <b>2,329</b>    | <b>6,159</b> |
| (+) Investment income allocated                           |                                       |                                    |                 | 2,800        |
| <b>Technical result in statutory financial statements</b> |                                       |                                    |                 | <b>8,959</b> |



### Premiums earned (net)

This represents the sum of premiums earned during the year, net of premiums attributable to reinsurers. Premiums earned follow the risk emergence pattern of the different types of policies. The earning patterns vary substantially and range from monthly earning of monthly billed premiums to earning a single premium received after only three years (extended warranty products).

### Claims incurred (net)

Comprises the sum of the claims paid and the change in the provision for claims outstanding during the financial year, net of reinsurance.

### Changes in other technical provisions

Not applicable.

### Expenses incurred

This represents all technical expenses incurred by the company in relation to its insurance operations.

### Underwriting result

The underwriting result was positive, with Health benefiting from the favourable run-off of the portfolio and the other lines performing relatively well as a result of an overall favourable claim (frequency) experience.

### Geographical areas

All business is underwritten in the EU and all risks are in the EU. An overview of premiums, claims and expenses by significant risk location is provided in the appended schedule 05.02.

## A.3 Investment Performance

### A.3.1 Investment holdings

The company's investment portfolio as at 31 December of the current period and the investment income generated in the period under review is as follows.

|                                  | Position as at end of period |             | Income for the period |             |
|----------------------------------|------------------------------|-------------|-----------------------|-------------|
|                                  | €'000                        | %           | €'000                 | %           |
| Government bonds (*)             | 11,731                       | 11%         | 642                   | 13%         |
| Corporate bonds (*)              | 73,503                       | 69%         | 3,209                 | 67%         |
| Loans to corporate borrowers (*) | 8,091                        | 8%          | 598                   | 12%         |
| Money markets                    | 8,535                        | 8%          | 276                   | 6%          |
| Cash and deposits                | 4,319                        | 4%          | 62                    | 1%          |
|                                  |                              |             | 4,787                 |             |
| Asset management expenses        |                              |             | -325                  |             |
| <b>Total</b>                     | <b>106,179</b>               | <b>100%</b> | <b>4,462</b>          | <b>100%</b> |

(\*) On Solvency II valuation basis, which includes accrued interest. See also at D.1.1.

Income for the period was positive as a consequence of the interest rate and spread decreases in the capital markets. Short term cash instruments yields remained relatively high, as in the prior year.

The income on the Loans to corporate borrowers was in line with expectations and is less volatile than that generated on the bond markets.

Except for one investment (Loans to corporate borrowers), the company holds a very liquid and diversified portfolio of relatively high credit standing. Investment income, consequently, is lower than that of a portfolio that would also hold less liquid fixed-income or equity instruments.

#### **A.4 Performance of other activities**

The company's only activity is that of Non-Life insurance business.

#### **A.5 Any other disclosures**

There is no other information required to be disclosed regarding the performance of the business.


## B System of governance

### B.1 General information on the system of governance

#### B.1.1 Governance structure

AEI’s system of governance is embedded within the overarching system of governance of the Assurant group. The design and effectiveness of system of governance is responsibility of the Board of Directors. The Board of Directors is supervised by an independent board of Supervisory Directors. The Board of Directors delegates responsibilities for certain functions to Key Function Holders (in blue in below table). The company maintains a governance map which documents the detailed implementation of the system of governance. This includes the terms of reference and detailed roles and responsibilities for the key function holders.

The governance structure is summarised in the picture below.



#### B.1.1.1 Supervisory Board

The Supervisory Board supervises the Board of Directors and oversees that the Board of Directors acts in accordance with the Company’s strategy, policies and objectives. It is collectively responsible for coaching and advising the Board of Directors when necessary.

##### Sub-Committee

The company’s Supervisory Board has established an Audit, Risk & Compliance Committee.

#### B.1.1.2 Board of Directors

The Board comprises the Chief Executive Officer (“CEO”), the Chief Financial Officer (“CFO”), and the Head of Risk.

The Board of Directors sets the strategy and business plan within the context of Assurant group’s plans and ensures that the necessary financial and human resources are in place to meet the organisation’s objectives.

### B.1.1.3 Key function holders

The Board of Directors has delegated the execution of certain key functions to senior management / key function holders. These are functions that have a material effect on the system of internal control in the business and influence material decision making. The key functions have been defined considering the requirements of Solvency 2 regulations and guidance from regulators. The key functions are as follows:

- Risk management
- Internal audit
- Actuarial (control)
- Compliance

Each Key Function Holder prepares a functional performance report to the board(s) on a quarterly basis (risk management & compliance) or annual basis (actuarial and internal audit).

The detailed responsibilities for each Key Function Holder are documented in the Governance Map which is reviewed and approved by the Board of Directors on a regular basis. This ensures that each Key Function Holder has the necessary authority and operational independence to carry out their role. On an annual basis, as part of the Business Planning process, each Key Function Holder will ensure that they have the necessary resources to deliver on their responsibilities. The Business plan is approved by the Board of Directors.

The responsibilities of each of the key-functions holders are summarised below.

- The Head of Risk, being a Board of Directors' member, attends and provides reporting to the Board of Directors' meetings and the Audit Risk & Compliance Committee meetings and has responsibility for the development and review of the risk management system, governance system and internal control system; implementation of risk management processes and systems; reporting on the risk profile of the business, preparation and presentation of the Own Risk and Solvency Assessment (ORSA).
- The 2<sup>nd</sup> line Actuary attends of the meetings of the Board of Directors at which his reporting is on the agenda. The 2<sup>nd</sup> line Actuary oversees all actuarial aspects of strategy and financial management. Oversight of the appropriateness of methodologies, models, bases of calculation of technical provisions; assessment of the sufficiency and quality of the data used in the calculation of technical provisions; reporting on the reliability and adequacy of the calculation of technical provision; advising of any concerns regarding the sufficiency of financial assets to meet liabilities to policies; the modelling of risk capital for the ORSA, including advising on suitable stress and scenario testing; reinsurance arrangements; oversight of investment strategy and asset-liability matching.
- The Head of Internal Audit provides reporting to the Board of Directors and to the Audit Risk & Compliance Committee and is responsible for providing reasonable assurance to the Board of Directors and the Audit Risk & Compliance Committee about the adequacy and effectiveness of the internal control environment including procedures, controls and policies and for the establishment of an annual audit plan.
- The Head of Compliance provides reporting to the Board of Directors and to the Audit Risk & Compliance Committee and is responsible for ensuring that the company fulfils its regulatory, legislative, and corporate standards and obligations and for assessing the adequacy of measures taken to prevent non-compliance. The Head of Compliance is also responsible for upholding sanction and anti-money-laundering measures.

### B.1.2 Material changes in the system of governance

In the reporting period, no material changes were made to the system of governance.

### **B.1.3 Information on the remuneration Policy**

The Board of Directors, management and employees of AEI are employed by Assurant Europe Services BV (AES). AEI and AES are under common management and AES applies the same practices that would have applied if management and employees would have been employed by AEI directly.

The Remuneration policy for the Board of Directors is set by the Annual General Meeting. The periodical determination of its remuneration is set by the Supervisory Board, in accordance with that Remuneration policy.

The Board of Directors, management and employees are remunerated as follows:

- Fixed remuneration, based on a (group wide) benchmark / role content basis.
- Variable remuneration, based on personal and company financial performance, such within the local legal limits applying (performance related variable remuneration up to 20% of fixed/guaranteed income).

Variable remuneration is not deferred.

Supervisory Board members receive a fixed fee.

### **B.1.4 Transactions with shareholders, with persons who exercise a significant influence on the undertaking, and with members of the administrative, management or supervisory body.**

In June, the company repaid share premium of EUR 15,767,184 to the shareholder. In September, it reduced the nominal value of shares resulting in a repayment to the shareholder of EUR 9,156,000.

### **B.1.5 Assessment of the adequacy of the system of governance**

The system of governance is set up in accordance with Solvency 2 guidelines and the design is assessed periodically.

The system of governance is periodically reviewed by the Board to ensure that it is effective and it provides for sound and prudent management of the business. Such reviews take into account the nature, scale and complexity of the business. The scope, findings and conclusions of such reviews are documented and reported to the Board with suitable feedback loops in place to ensure that any follow-up actions are undertaken and recorded.

Based upon the most recent internal review conducted, the Board has assessed the system of governance to be adequate and appropriate to the nature, scale and complexity of the risks inherent in the business.

Key Function Holders and External audit have direct access to the Audit Risk & Compliance Committee and the Supervisory Board to share any concerns they may have about the governance framework.

## B.2 Fit and proper requirements

The company has a Fit and proper policy that addresses that appropriate resource are in place to deliver effective and efficient management of the business. The Company takes appropriate steps to ensure that (senior) managers, individuals responsible for key functions and those working in key functions are fit and proper to carry their responsibilities. The requirements are proportionate to the role and responsibilities of the position. Checks are made on initial appointment and are re-assessed when deemed required. The results of all assessments are reported to the Board of Directors. For new employees, these tests included some or all of the following:

- Criminal record checks.
- Credit referencing.
- Curriculum Vitae detailing skills, qualifications and experience.
- Continuous professional development / performance management framework.
- Membership of professional institutes.
- The recruitment and selection process in place at the time of appointment.
- Permanent education requirements, which are reported on quarterly and monitored by the Compliance Officer.

## B.3 Risk management system including the own risk and solvency assessment

### B.3.1.1 Risk Management System

AEI has established a risk management system which comprises:

- (a) a strategy;
- (b) risk management and internal control policies;
- (c) risk management processes;
- (d) control activities.

In addition, it includes a risk management system review; reporting and disclosure; independent assurance and regulatory compliance monitoring.

The risk management system applies to all categories of risk, and, unless stated otherwise, the following information applies for each separate risk category.

### B.3.1.2 Risk management strategy

AEI's risk management strategy ensures that the company's risk appetite is not exceeded. Risks are assessed, defined and approached in one of the following four ways, depending on the nature of the risk and related circumstances:

- Risk acceptance: AEI accepts risks that fall within the boundaries/limits defined in the risk appetite statement. Any risk falling outside the specified limits or boundaries is reviewed to ascertain if the risk appetite requires updating or if an exception should be granted.
- Risk reduction/minimisation: these activities generally relate to control and mitigation activities, and therefore this strategy may include, amongst others, any or all of the following: the design of new process or accounting controls, contracting controls, changes in product design, improvement in a set of Terms and Conditions, or other changes designed to control and/or mitigate risk.
- Risk transfer: risk is transferred principally through reinsurance agreements. These may include, but are not limited to stop loss, excess of loss, quota share, or other such treaties. Other types of risk transfer can also be considered.

- Risk Avoidance: where an activity is outside the risk appetite of the AEI, AEI will seek to avoid exposure to that type of risk.

### B.3.1.3 Process

AEI implemented the three lines of defence model and enforces the requirement for first line management of risk, with oversight and challenge from the second line risk, actuarial and compliance functions and third line internal audit function confirmation, as follows.

|                     |   |  |
|---------------------|---|--|
| Oversight           | Supervisory Board   | <ul style="list-style-type: none"> <li>• Supervisory Board - independent oversight of Board of Directors</li> </ul>  |
| Responsibility      | Board of Directors  | <ul style="list-style-type: none"> <li>• Establishes risk appetite and strategy</li> <li>• Responsible for 1<sup>st</sup> and 2<sup>nd</sup> line activities</li> </ul>  |
| 3rd Line of Defence | Internal Advisory Services (Internal Audit)                           | <ul style="list-style-type: none"> <li>• Provides independent assurance on the effectiveness of first and second line of defence functions</li> </ul>  |
| 2nd Line of Defence | Risk Management Function<br>Compliance Function<br>Actuarial Function | <ul style="list-style-type: none"> <li>• Design, interpret and develop overall risk management framework</li> <li>• Overview of AEI risk registers</li> <li>• Monitor controls in place against key risks</li> <li>• Challenges risk mitigation and acceptance</li> <li>• Reports on risk exposures, issues, mitigations, and resolutions</li> </ul> |
| 1st Line of Defence | Business / Functions  | <ul style="list-style-type: none"> <li>• Executive risk owners</li> <li>• Owner of the risk management process</li> <li>• Identifies, manages, and mitigates risks</li> <li>• Identifies, manages, and reports on issues</li> </ul>  |


Business areas are responsible for completing quarterly Risk and Control Self-Assessments (RCSAs) which contribute to the Risk Register of the business.

### B.3.2 Own Risk and Solvency Assessment

AEI annually conducts an Own Risk and Solvency Assessment (ORSA). This assessment considers the company's strategy, its operating environment, and the risks to which it is exposed and results in a forward-looking assessment of the potential risks and capital impacts which the company uses to assess its current and future capital needs.

## ORSA Process

The table below show the steps in the ORSA process.



## B.4 Internal control system

### B.4.1 Description of system of internal control

AEI’s internal control system is designed to provide reasonable assurance that its reporting is reliable, compliant with applicable laws and regulations and its operations are effectively controlled.

The Company operates a “three lines of defence model” for the management of risks and performance of internal control, which is adapted and applied for a company of the size and complexity of AEI. This is illustrated in the overview below. Broadly this means that the risk function is responsible for providing a framework for risk management and internal control, the business functions are responsible for implementing the framework and the Internal audit function is responsible for independently validating the appropriateness of both the design and its implementation. The actuarial and compliance functions also provide second line challenge, oversight and assurance.





## B.4.2 Implementation of the compliance function

The Compliance Function operates within Assurant group's broader risk management framework and:

- is responsible for oversight and monitoring of compliance risk management and related control systems.
- supports the Board of Directors in managing compliance risks and embedding a culture of integrity in the organisation.
- develops the enterprise compliance strategy, structure, and processes of adherence to ethical standards and applicable rules and regulations.
- supports implementation of the compliance program and establishes and maintains effective compliance management and control systems.

The Compliance Function is independent of and takes an objective view on the operational activities of AEI. It provides timely advice to the Board of Directors or, where applicable the Supervisory Board on compliance related matters. If and when potentially significant misconduct in connection with AEI's business is detected, it ensures that reasonable steps are taken to respond to and resolve the (potential) misconduct. It oversees effective whistleblowing reporting channels and conducts or coordinates internal investigations of compliance violations. It develops and implements compliance policies and procedures, education, and trainings, and keeps abreast of regulatory and industry trends.

At least on an annual basis, the Compliance Function will draft the compliance plan, which describes the monitoring activities which the Compliance Function will perform, considering the risk ratings, supervisor priorities and audit results. The monitoring activities will be executed accordingly.

## B.5 Internal audit function

### B.5.1 Description of how the internal audit function is implemented

AEI's Head of Internal Audit (HoIA) is responsible for internal audit activities, in coordination with Assurant Inc.'s group Internal Audit Services (IAS) function. The HoIA is accountable to the Audit Risk & Compliance Committee (ARCC) of the Supervisory Board and has administrative responsibility to AEI's Chief Executive Officer.

The HoIA is responsible for regularly assessing the adequacy of governance, risk management and the internal controls system and reports his findings to the Board of Directors and the Audit Risk & Compliance Committee of the Supervisory Board.

Internal audit activities are coordinated with IAS as to ensure coordination of audit plans, coordination of resource planning, alignment on audit process, reporting and follow-up monitoring.

The annual audit plan (based on a three-year cycle) is prepared and submitted to the Supervisory Board for review and confirmation. Upon confirmation, the HoIA distributes the plan to business leaders and executes the plan during the course of the audit plan period. Additionally, at HoIA discretion or at the request of the ARCC, or management, other unannounced audits may be performed.

Initially the entire risk universe is considered during annual audit planning and subsequent revisions to plan, the highest-risk items are included as risk-based audits. Certain processes, while not rising to a level of significant risk, are still included on a cyclical basis to ensure breadth of coverage over a span of time.

Secondly, risks associated to the audit are identified and their mitigation evaluated via an assessment of the design and operational effectiveness of key internal controls, information systems, governance, risk management, and financial reporting supplemented where necessary by a programme of testing, creating audit programs for every project.

### **B.5.2 Description of how the internal audit function maintains independence and objectivity**

The Internal audit function's mandate and responsibilities are documented in the Internal Audit Charter. It defines the framework for the activities of the Internal Audit function and is approved by the Supervisory Board. The charter allows Internal audit to be independent of the functions audited and it provides full, free, and unrestricted access to all operations, records, property, and personnel. Additionally, it provides the authority to allocate resources, set frequencies, select subjects, determine scope of work, and apply the techniques required to accomplish audit objectives.

## **B.6 Actuarial function**

The Board of Directors appoints the Actuarial Function Holder. The holder needs to meet the fit and proper requirements and hold an appropriate practicing certificate from the Actuarial Society (Actuarieel Genootschap) or a comparable foreign qualification.

The Actuarial Function Holder reports to the Head of Risk for management purposes but has a line of escalation to the Supervisory Board (via the Audit Risk & Compliance Committee).

The responsibilities of the Actuarial Function Holder are defined in a Charter. As part of ensuring responsibilities are carried out in an effective and efficient manner, the Actuarial function operates in close cooperation with the members of the 1<sup>st</sup> line actuarial function team.

The Actuarial Function Holder coordinates the calculation of technical provisions, provides opinions on the underwriting policy and reinsurance arrangements, and contributes to the effectiveness of the risk management system.

The actuarial function is responsible for the process of calculating the technical provisions, as well as for the calculation of the SCR and the MCR. In addition, the actuarial function is responsible for reviewing and calculating the appropriateness of insurance product pricing and contributing to the governance committees, capital initiatives and regulatory returns where appropriate.

The Actuarial Function Holder provides quarterly updates and an annual report to the Board of Directors and the Supervisory Board, detailing the methodology, assumptions, and results of its work.

## **B.7 Outsourcing**

AEI operates as part of the Assurant group and is tightly linked to the European - and partially, US - operations. The company does not employ staff itself but instead benefits from shared services centres and centres of excellence and has entered into service agreements with the group entities that provide these services.

Similarly, AEI does often not employ its own claim-adjusters and policy maintenance staff but instead engages third parties that have proven expertise in dealing with electronic devices and digital customer experience journeys. Assurant group employees supervise such third parties, based on detailed service level agreements.

In the Netherlands, Assurant employees are employed by Assurant Europe Services B.V., a group company under the same management as AEI. The activities of these employees are not considered "outsourcing".

AEI distinguishes between two types of outsourcing:

- Activities for which the Board of Directors cannot outsource functional responsibility but for which AEI makes use of individuals and infrastructure that are employed or owned by other group entities. These activities are managed as if directly employed /owned by AEI and are not considered “outsourcing”.
- Activities for which functional responsibility can be outsourced and which is considered critical or important outsourcing as defined by Solvency 2 definitions.

AEI’s Outsourcing policy sets the standards and controls required for selection of internal and external service providers as well as the requirements for ongoing management of such providers, with the aim of ensuring adequate oversight and governance of performance.

Critical or important outsourced functions are:

| Outsourced Function                         | Outsourced to                    |
|---|----------------------------------|
| IT & infrastructure management              | Assurant group companies (US/UK) |
| Oversight over third party administrators   | Assurant group companies (UK)    |
| Financial administration                    | Assurant group companies (UK)    |
| Policy administration and claims management | Various third parties (EU)       |


## **B.8 Any other disclosures**

None.

## C Risk management

The sections below provide a qualitative and quantitative summary of the risk profile for each category of risk. Where information is specific to each risk category it has been set out under the relevant heading. Where the information is common across all risk categories it has been included in Section C.7.

AEI is mainly exposed to Non-Life underwriting risk. The chart below shows the distribution of the gross SCRs by risk module (excluding the diversification effects between the risk modules) as at current and prior year-end.



The risk profile has not changed materially compared to the prior period. The main variance is a decrease in Market risk, as the invested assets have reduced over the year following the repayment of share premium reserve and share capital for an amount of EUR 24.9m in total.

### C.1 Underwriting risk

#### C.1.1 Qualitative review of risk profile

##### Non-Life Underwriting Risk - Premium and Reserve Risk

AEI is exposed to the risk of having to pay more claims, or incur higher than expected costs per claim, than foreseen when pricing its insurance products. Its insurance risk is generally more driven by claim frequency as the insurances generally cover high volume low value categories. Depending on the individual program, the risk concerning the cost of individual claims may have been negated by up-front agreements with original or alternative manufacturers of parts or devices.

##### Non-Life Underwriting Risk - Lapse Risk

Lapse risk arises mainly due to the loss of future income if lapses are higher than expected. Lapse risk can be driven by external events such as an economic recession or by internal factors such as poor customer service delivery.

##### Non-Life Underwriting Risk - Catastrophe Risk

In some territories AEI is exposed to this risk, for example due to floods or windstorm. This risk is generally remote.

### Health SLT Underwriting Risk - Mortality and Longevity Risk

AEI has a (very) small exposure to mortality and longevity risk as the duration of payment of periodical benefit payments to insured is dependent on the average expected lifetime of each insured.

### Health SLT Underwriting Risk - Disability-Morbidity Risk

AEI is exposed to disability-morbidity risk; the probability of having to pay out more benefits due to increased disability-morbidity.

In case of annuities, disability-morbidity risk carries the possibility of recovery, meaning insureds can recover from their illness and benefits can cease to be paid at that point. Some covers involve a lump sum payment only.

AEI did not write policies on a standalone basis, but as wrappers to consumer borrowing arrangements, like mortgage loans or consumer credits, meaning they were less exposed to disability-morbidity risk compared to insureds that had a health driven incentive to buy protection.

### Health SLT Underwriting Risk - Health Expense Risk

The Company is exposed to expense risk. This arises if future expenses turn out to be higher than expected or higher than those provisions are carried for. Cost increases have different causes, such as non-recurring regulatory change costs, or recurring inflation increases. This risk can be mitigated only partially.

### Health SLT Underwriting Risk - Revision Risk

Revision risk applies to annuity insurances where the benefits 'could increase because of changes in inflation, the legal environment or the state of health of the person insured.' AEI's insurances do not provide such benefits; therefore, this risk is not applicable.

### Health SLT Underwriting Risk - Lapse Risk

Lapse risk arises mainly due to the loss of future income if lapses are higher than expected. Lapse risk can be driven by external events such as an economic recession or by internal factors such as poor customer service delivery.

### Health Underwriting Risk - Catastrophe Risk


Health Catastrophe Risk applies in the event that a natural catastrophe event would impact the company's insureds, for example due to becoming disabled by such event. The portfolio does not have concentrations of insured through and the exposure is not material.

### Health Underwriting risk - Unemployment

AEI is exposed to the risk of unemployment. The Company did not write this risk on a standalone basis, but as a wrapper to a consumer borrowing arrangement, like a mortgage loan or consumer credit. The risk of unemployment tends to be related to the stages of the economic cycle. The Company is not exposed to unemployment risk in a particular industry or region.


### C.1.2 Quantitative review of risk profile

The graphs below show the underwriting risk profile of the Company using the risk capital requirements calculated by the standard formula as at 31 December of the current and prior year.



The relative contributions of Non-Life Underwriting Risk and Health Underwriting Risk were in line with prior year.


The development of the SCR for Non-Life Underwriting Risk is illustrated below.



Most of the Non-Life Underwriting Risk SCR is made up by Premium and Reserve Risk, which is common for a Non-Life insurer. Catastrophe risk is relatively low as the terms and conditions of many products exclude catastrophe risk or the policies are written in a territory where catastrophe risk is covered by national schemes.

The SCR for Lapse risk increased in 2024, with growing volumes and improved profitability of some insurance programs.

The development within the SCR for Health SLT Underwriting Risk is illustrated below.



The use of a similar to life techniques model for the Health portfolio implies the inclusion of all future cashflows, up to expiry of each policy. Since more premiums will be received than claims will be paid, the SCR for Lapse risk reflects that in case of lapse of policies, the company would on a net basis receive less future cashflows.

### C.1.3 Risk mitigation techniques

The below table sets out the techniques used for mitigating (material) risks and the processes used for monitoring their continued effectiveness.

| Risk Category   | Key Controls and Risk Mitigation Techniques   |
|---|---|
| Premium & reserve risk (Non-Life)   | <ul style="list-style-type: none"> <li>Underwriting guidelines include conditions that limit maximum duration of individual policies and claim re-pricing rights for policies that have a longer duration.</li> <li>Underwriting practices allow for profit-sharing mechanisms due to which the interests of AEI and its program client are more closely aligned.</li> <li>Reinsurance guidelines prescribe the use of reinsurance if the underwriting risk is outside of AEI's risk appetite.</li> <li>Regular experience investigations and monthly review of programs avoid insufficient technical provisions.</li> <li>Emerging risk reviews focus on market developments that may prove a program under-reserved.</li> </ul> |
| Underwriting risk - Disability/Morbidity Risk/ Unemployment Risk (Health SLT) | <ul style="list-style-type: none"> <li>Regular experience investigations, and industry analysis, to support best estimate assumptions and identify trends.</li> <li>Policy conditions include (low) limits in amount and duration of payment(s).</li> </ul>   |
| Expense Risk  | <ul style="list-style-type: none"> <li>Stringent regime of budgetary control, monitored as part of the annual planning and quarterly reporting cycles.</li> <li>Outsourcing strategy keeps costs variable.</li> </ul>   |
| Lapse Risk  | <ul style="list-style-type: none"> <li>Regular experience investigations to support best estimate assumptions and identify trends.</li> <li>Stringent management of customer service delivery and adherence to treating customers fairly (TCF) principles.</li> </ul>   |

| Risk Category    | Key Controls and Risk Mitigation Techniques  |
|------------------|--|
| Catastrophe Risk | <ul style="list-style-type: none"> <li>Given low exposure to this risk, no specific mitigation measures are in place.</li> </ul> |

## C.2 Market risk

### C.2.1 Qualitative review of risk profile

Market risk emerges in different ways. It arises directly, because of interest rate and spread movements or exchange rate movements but also due to a loss of funds if a debtor is not able to repay its debt. This indirect risk is credit risk and therefore also treated in section C.3.


AEI does not seek market risk to increase revenue or profit but rather incurs it as a consequence of having to invest funds to cover policyholder liabilities and hold capital for regulatory purposes.

The following risk categories are included within market risk.

| Risk category      | Description   |
|--------------------|---|
| Interest Rate Risk | Interest risk is inherently present. Given that a major part of AEI's assets are bonds, interest fluctuations will impact these assets' values. Fluctuations in interest rates also affect liabilities' values. The overall impact of interest risk is therefore depending on how well the assets and liabilities are matched. Given that AEI has a larger exposure on interest sensitive assets than exposure on liabilities, decreasing interest rates are beneficial to its solvency position. |
| Spread Risk        | Given the large share of corporate bonds in its asset portfolio, AEI is exposed to spread risk. Spread is the part of the interest rate above the risk-free rate. When spreads increase, the market value of assets reduces.  |
| Currency Risk      | Currency risk emerges when currencies lose value compared to the Euro, the companies reporting currency. AEI only operates in the European Union, and therefore its exposure to currency risk is limited.   |
| Concentration Risk | Depending on the diversity of the investment portfolio, concentration risk can emerge.  |
| Equity risk        | AEI had no exposure to equity risk as at 31 December.   |
| Property Risk      | AEI had no exposure to property risk as at 31 December.   |



### C.2.2 Quantitative review of risk profile



The company is exposed mostly to interest-rate risk and spread risk, both as a result of investing its Own funds mostly in a corporate bonds portfolio. Spread risk is the largest category as there are no off-sets available in liabilities, unlike for interest rate risk.

Currency risk is small as this concerns business underwritten outside of the Euro-zone only.

Concentration risk is nil, as the company’s investment policy contains concentration limits that are stricter than those allowed by Solvency 2 standard model.

### C.2.3 Risk mitigation

The below table sets out the techniques used for mitigating risks and the processes used for monitoring their continued effectiveness.

| Risk Category      | Key Controls and Risk Mitigation Techniques   |
|--------------------|---|
| Interest Risk      | Matching of assets and liabilities to reduce the impact of adverse interest rate movements.   |
| Spread risk        | Investing in Investment grade bonds only, with diversification over many regions and sectors.   |
| Concentration Risk | Diversified portfolio of investments with smaller notional exposures to avoid concentration of risk.  |
| Currency Risk      | Investments in Euro bonds only. For non-Eurozone exposures maintain current accounts in these currencies against the liabilities denominated in these currencies. |

The company does not use any derivatives or other specific risk mitigation instruments to manage its market risk exposure.

## C.2.5 Assets invested in accordance with the Prudent person principle.

### C.2.5.1 Prudent Person Principle

The Company holds assets to back its various liabilities and its shareholder funds. Through pro-active investment management the Company can achieve an appropriate level of investment return. Achieving an appropriate level of investment return is not the sole aim though, as the Company needs to keep the risks within its risk tolerance limits, which are set with the aim to achieve pay outs in line with policyholders' reasonable expectations.

The Company has a limited risk appetite to incur losses on investments that are held to cover policyholder liabilities. These investments are held to match the best estimate cash outflows and returns on funds are of lower priority (since the liabilities do not hold guarantees and are discounted against the EIOPA curve).

The Company has a higher risk appetite for invested shareholder funds. For these, return on investment has a higher priority and with that comes a more positive risk appetite towards credit and spread risk.

Finally, the Company has a limited risk appetite for liquidity risk and concentration risk. Subsequently, when setting the asset mix and determining suitable investments it is important to maintain a minimum level of cash holdings and to ensure that the company does not invest too much with a single counterparty, for which strict limits exist.

### C.2.5.2 Investment management

The Board of Directors is responsible for ensuring that the controls for investment management are appropriate and effective. As such the board is responsible for the approval of the Investment policy and oversight of its operation. This includes signing off major changes in the approach used for investment management. At AEI, also the Supervisory Board signs off the Investment policy.

## C.3 Credit risk

### C.3.1 Qualitative review of risk profile

Two types of exposures are distinguished:

#### Type 1

The Company holds significant amounts of funds with banks in The Netherlands. Counterparty default risk would emerge if one or more of these banks would not be able to repay the balances held.

The Company has placed reinsurance with certain reinsurers, for specific programs in its portfolio. From time to time the Company has significant amounts receivable, both current and future, from these reinsurers.


#### Type 2

The company has significant amounts due from intermediaries.

Spread risk, reflecting credit risk on the corporate bond portfolio, is treated in paragraph C.2.

### C.3.2 Quantitative review of risk profile

The graphs below show the credit risk profile of the Company using the risk capital requirements calculated by the standard formula as at 31 December of current and prior year.



In comparison, the credit risk on the bond portfolio is larger than that associated with type 1 and 2 exposures. The capital held for type 1 exposures is relatively modest as exposure to reinsurers is mostly covered by liabilities or collateral and exposure to banks is mainly to higher rated banks (which also are Globally Systemic Important Banks).

Type 2 exposure is growing in line with the growth of the portfolio. In relative terms the risk is modest, as many programs know monthly premium cycles or single premium payments up-front.

### C.3.3 Risk mitigation

The below table sets out the techniques used for mitigating risks and the processes used for monitoring their continued effectiveness.

| Risk Category                   | Key Controls and Risk Mitigation Techniques   |
|---------------------------------|---|
| Credit and counterparty default | <ul style="list-style-type: none"> <li>▪ Operation of controls which limit the level of exposure to any single counterparty and impose limits on exposure by credit rating.</li> <li>▪ Product design allowing for cancellation of coverage when premiums unpaid.</li> <li>▪ Bank accounts held with G-SIBs.</li> <li>▪ Reinsurance treaties only with highly rated reinsurers and/or with set-off and collateral clauses.</li> </ul> |

## C.4 Liquidity risk

Liquidity risk is defined as the risk that the company will have insufficient liquid assets available to meet liabilities as they become due.

### C.4.1 Qualitative review of risk profile

Liquidity risk arises when cash outflows to policyholders or pay-out patterns deviate from expectations, or when cash outflows are not properly matched by cash inflows. The company holds almost all its invested assets in liquid instruments (cash at bank and government and corporate bonds) which are directly or almost directly available. The only illiquid investment is in a closed fund that originates private loans, which accounts for 7.9% of total invested assets. Therefore, liquidity risk is not considered a major residual risk.

Other liquidity issues could arise from counterparty default risk (see section C.3).

### C.4.2 Quantitative review of risk profile

Given the very large excess of liquid investments over policyholder liabilities, no further details are provided.

### C.4.3 Risk mitigation

The below table sets out the techniques used for mitigating risks and the processes used for monitoring their continued effectiveness.

| Risk Category | Key Controls and Risk Mitigation Techniques   |
|---------------|---|
| Liquidity     | <ul style="list-style-type: none"> <li>▪ Funds held at GSIB banks with limits per institution.</li> <li>▪ Investment policy prescribes investment in liquid assets.</li> <li>▪ Quarterly cash flow forecasts to anticipate funding requirements over the following three months and considering wider funding requirements from the business planning and/or group dividend payments.</li> <li>▪ Weekly / monthly / quarterly treasury reporting showing the liquid assets held and how these compare to the minimum threshold set in the Investment policy.</li> <li>▪ ORSA liquidity stress scenarios.</li> </ul> |

### C.4.5 Expected Profit in Future Premiums

As required by Article 260(2) of the S2 Directive, the company calculated the amount of discounted expected profit in future premiums included in the best estimate technical provisions.

|                                    | 2024          | 2023          |
|------------------------------------|---------------|---------------|
| €'000                              |               |               |
| Expected profit in future premiums | 41,784        | 42,644        |
| <b>Total EPIFP</b>                 | <b>41,784</b> | <b>42,644</b> |

## C.5 Operational risk

### C.5.1 Qualitative review of risk profile

The company typically carries the same operational risks as most insurers. Operational risks manifest themselves in a wide variety of forms. The company is considered to be most exposed to IT-related risks (continuity of processing, data security, data privacy) and regulation related risks (changes in regulation that increase the cost base or changes in regulations that are applied retro-actively and for which no means of compensation exists). Other categories of operational risk that the company is exposed to, either directly or via its business partners / outsource partners, are:

- Supply chain and customer experience interruptions (IT or otherwise)
- Internal or external fraud
- Conduct and reputational risk

Operational risks are assessed periodically and captured in a risk register.

### C.5.2 Quantitative review of risk profile

In the first section of this chapter C, a graph shows the distribution of the four main risk groups that are part of the SCR, including operational risk, calculated by the standard formula as at 31 December of the current and prior period. This graph shows that as at current year-end operational risk is, from a quantitative perspective, relatively material, contributing circa 10% of its final SCR.

Whilst the company is exposed to many operational risks and has quantified the (external) cost of these scenarios, the impact of each scenario does not exceed the SCR as determined at 31 December.

### C.5.3 Risk mitigation

The below table sets out the techniques used for mitigating risks and the processes used for monitoring their continued effectiveness.

| Risk Category    | Key Controls and Risk Mitigation Techniques   |
|------------------|---|
| Operational risk | <ul style="list-style-type: none"> <li>▪ Close oversight of the performance and risk management of (IT-) service providers.</li> <li>▪ SOX review of major IT applications.</li> <li>▪ Ongoing monitoring and testing of business continuity plans.</li> <li>▪ (Preventive) health and safety measures.</li> <li>▪ Remote work facilities.</li> </ul> |

## C.6 Other material risks

In 2024, following elections, the US administration has imposed, and other countries counter-imposed, a number of import tariffs. These do currently not significantly impact the company's operations, but this may change if the number of products in scope increase.

AEI's products often but not always provide fixed claim payment for a loss event and are therefore partially impacted by (sustained) inflation. AEI's expense provisions are considered sufficiently robust but it should be recognised that a prolonged period of higher than usual inflation would impact the company at some point in time.

## C.7 Any other disclosures

### C.7.1 Risk mitigation techniques and monitoring

#### Risk assessment

Section B.3.1 sets out the Risk management framework of the Company and section B.3.2 explains how the Company carries out its Own Risk and Solvency Assessment (ORSA). This provides the framework by which individual risks are identified, assessed, monitored and managed. As part of this framework, the Company quantifies the capital impact of different risks by:

- Determining the risk capital requirements using the standard formula as part of the quarterly financial reporting cycle.
- Performing additional stress and scenario testing to support the ORSA.

An assessment is carried out on an annual basis to confirm that the standard formula remains appropriate for establishing the regulatory capital requirements for the Company. This assessment is approved by the Board of Directors.

### C.7.2 Stress testing and sensitivity analysis

#### C.7.2.1 Overview

The Company uses the standard formula to determine its regulatory capital requirements, and these are calculated and reported on a quarterly basis. As part of the Own Risk and Solvency Assessment (ORSA) the Company performs a forward-looking assessment of its ability to meet the regulatory capital requirements under a range of stresses and scenarios.

Full details of the stresses and scenarios, the methodologies used and the results are included in the ORSA report will be submitted to DNB.

#### C.7.2.2 Methodology

The stress and scenario tests are carried out with a base date of 31 December 2024.

In quantifying the financial impact of each stress, it is assumed that each stress occurs immediately after the year-end, i.e., as at 1 January 2025.

After applying the stress, risk capital is recalculated in accordance with the standard formula in order to re-establish the regulatory capital requirements.

#### C.7.2.3 Outcomes from the stress and scenario testing

Each stress and scenario test was performed using the methodology described above, and the Solvency ratio was compared to the base financial position. The analysis concluded that the amount of available capital at 31 December 2024 is sufficient to withstand the stresses and scenarios adopted by the Board of Directors.

## D Valuation for Solvency purposes

This section of the Solvency and Financial Condition Report shows how the assets and liabilities of the Company have been valued, both for solvency and statutory reporting purposes. The below table summarises the Own funds (as measured on a solvency basis) and net assets (as measured on a statutory basis) and provides a reference where further information is provided:

| €'000                         |             | Solvency 2    | Statutory     |
|-------------------------------|-------------|---------------|---------------|
| Assets                        | Section D.1 | 179,273       | 254,611       |
| Technical provisions          | Section D.2 | 16,705        | 142,758       |
| Other liabilities             | Section D.3 | 73,528        | 67,346        |
| <b>Own funds / net assets</b> |             | <b>89,040</b> | <b>44,508</b> |

### D.1 Assets

The table below shows separately each class of asset with Solvency 2 and statutory account value:

|  | Para.        | Solvency II        | Statutory          |
|--|--------------|--------------------|--------------------|
|  |              | value              | accounts value     |
|  |              | C0010              | C0020              |
| <b>Assets</b>  |              |                    |                    |
| R0010 Goodwill   |              |                    | 0                  |
| R0020 Deferred acquisition costs   | <b>D 1.1</b> |                    | 61,818,652         |
| R0030 Intangible assets  |              | 0                  | 0                  |
| R0040 Deferred tax assets  | <b>D 1.2</b> | 0                  | 484,981            |
| R0050 Pension benefit surplus  |              | 0                  | 0                  |
| R0060 Property, plant & equipment held for own use   |              | 0                  | 0                  |
| R0070 Investments (other than assets held for index-linked and unit-linked contracts)        |              | 101,859,951        | 100,916,747        |
| R0080 Property (other than for own use)  |              | 0                  | 0                  |
| R0090 Holdings in related undertakings, including participations                             |              | 0                  | 0                  |
| R0100 Equities   |              | 0                  | 0                  |
| R0130 Bonds  | <b>D 1.3</b> | 85,234,279         | 84,445,301         |
| R0140 Government Bonds   |              | 11,730,885         | 11,687,428         |
| R0150 Corporate Bonds  |              | 73,503,394         | 72,757,872         |
| R0160 Structured notes   |              | 0                  | 0                  |
| R0170 Collateralised securities  |              | 0                  | 0                  |
| R0180 Collective Investments Undertakings  |              | 16,625,672         | 16,471,446         |
| R0190 Derivatives  |              | 0                  | 0                  |
| R0200 Deposits other than cash equivalents   |              | 0                  | 0                  |
| R0210 Other investments  |              | 0                  | 0                  |
| R0220 Assets held for index-linked and unit-linked contracts                                 |              | 0                  | 0                  |
| R0230 Loans and mortgages  |              | 0                  | 0                  |
| R0240 Loans on policies  |              | 0                  | 0                  |
| R0250 Loans and mortgages to individuals   |              | 0                  | 0                  |
| R0260 Other loans and mortgages  |              | 0                  | 0                  |
| R0270 Reinsurance recoverables from:   | <b>D 2</b>   | 4,793,857          | 26,295,812         |
| R0280 Non-Life and Health similar to Non-Life  |              | 4,784,104          | 26,295,812         |
| R0290 Non-Life excluding Health  |              | 4,784,104          | 26,295,812         |
| R0300 Health similar to Non-Life   |              | 0                  | 0                  |
| R0310 Life and Health similar to Life, excluding Health and index-linked and unit-linked     |              | 9,753              | 0                  |
| R0320 Health similar to Life   |              | 9,753              | 0                  |
| R0330 Life excluding Health and index-linked and unit-linked                                 |              | 0                  | 0                  |
| R0340 Life index-linked and unit-linked  |              | 0                  | 0                  |
| R0350 Deposits to cedants  |              | 0                  | 0                  |
| R0360 Insurance and intermediaries receivables   | <b>D 1.4</b> | 60,770,423         | 78,207,438         |
| R0370 Reinsurance receivables  |              | 0                  | 0                  |
| R0380 Receivables (trade, not insurance)   | <b>D 1.5</b> | 7,529,748          | 8,864,286          |
| R0390 Own shares (held directly)   |              | 0                  | 0                  |
| R0400 Amounts due in respect of own fund items or initial fund called up but not yet paid in |              | 0                  | 0                  |
| R0410 Cash and cash equivalents  | <b>D 1.6</b> | 4,319,324          | 4,319,324          |
| R0420 Any other assets, not elsewhere shown  |              | 0                  | 0                  |
| R0500 <b>Total assets</b>  |              | <b>179,273,303</b> | <b>280,907,239</b> |

The following table provides the differences between the value of total assets between the statutory financial statements and the column statutory values in Schedule 02.01:

|   | Row   | 2024           |
|---|-------|----------------|
| €'000   |       |                |
| Total assets in statutory financial statements  |       | 254,611        |
| Reclassification of reinsurance share of provision for unearned premiums (statutory deducted from liabilities)  | R0270 | 23,802         |
| Reclassification of reinsurance share of provision for claims outstanding (statutory deducted from liabilities) | R0270 | 2,494          |
| <b>Total assets in statutory column in Schedule 02.01</b>   |       | <b>280,907</b> |

#### D.1.1 Deferred acquisition costs

In Solvency 2, deferred acquisition costs, not being a future cashflow, are valued at nil.

#### D.1.2 Deferred tax assets

The deferred tax asset represents a tax claim out of a temporary difference between the statutory financial statements and the tax accounts. In the statutory accounts this presents the only deferred tax position. In the Solvency 2 balance sheet this item is presented on a net basis in the liability section.

#### D.1.3 Bonds

Bonds are measured at fair value.

The difference between the Solvency 2 and statutory value of investments is due to a difference in the classification of accrued investment income, which is recognised within Investments in Solvency 2 and within Receivables (trade, not insurance) in the statutory financial statements.

|   | Row   | 2024          |
|---|-------|---------------|
| €'000   |       |               |
| Bonds in the statutory accounts               | R0130 | 84,445        |
| Reclassification of accrued interest to Bonds | R0380 | 789           |
| <b>Bonds in Solvency 2</b>                    |       | <b>85,234</b> |

#### D.1.4 Collective Investment Undertakings

Collective Investment Undertakings are measured at fair value.

For illiquid investments, the statutory valuation principle is historical cost adjusted for other than temporary impairments in value if deemed necessary. For Money market funds, valuation is at market value for both statutory and solvency purposes.



|  | Row   | 2024          |
|--|-------|---------------|
| €'000  |       |               |
| Collective Investment Undertakings in the statutory accounts | R0180 | 16,471        |
| Revaluation to fair value                                    |       | 154           |
| <b>Collective Investment Undertakings in Solvency 2</b>      |       | <b>16,626</b> |

#### D.1.5 Insurance and Intermediaries receivables

Insurance and intermediary receivables are measured at the undiscounted amount of the cash or other consideration expected to be received, net of any allowance for impairment.

|   | Row   | 2024          |
|---|-------|---------------|
| €'000   |       |               |
| Amounts due from policyholders in the statutory accounts                          |       | 1,563         |
| Amounts due from intermediaries in the statutory accounts                         |       | 76,644        |
| Insurance and intermediary receivables in statutory column in 02.01               | R0360 | 78,207        |
| Reclassification of premiums and commissions not yet due to technical provisions: |       |               |
| From amounts due from policyholders   |       | -694          |
| From amounts due from intermediaries  |       | -16,744       |
|   | R0360 | -17,437       |
| <b>Insurance and intermediary receivables in Solvency 2</b>                       |       | <b>60,770</b> |

#### D.1.6 Receivables (trade, not insurance)

Trade receivables are measured at the undiscounted amount of the cash or other consideration expected to be received, net of any allowance for impairment.

|  | Row   | 2024         |
|--|-------|--------------|
| €'000  |       |              |
| Receivables (trade, not insurance) in statutory accounts         |       | 7,530        |
| Inventory  |       | 363          |
| Other prepayments and accrued income                             |       | 972          |
| Receivables (trade, not insurance) in statutory column in 02.01  | R0380 | 8,864        |
| Reclassification of accrued interest to Bonds                    | R0130 | -789         |
| Reclassification of inventory held for claims fulfilment in kind | R0540 | -363         |
| Prepayments not recognised in solvency 2                         | R0380 | -183         |
| <b>Receivables (trade, not insurance) in Solvency 2</b>          |       | <b>7,530</b> |

## D.1.7 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks and other short-term highly liquid investments and are measured at fair value. Highly liquid is defined as having a short maturity of three months or less at acquisition.

## D.2 Technical provisions

The following table shows the net technical provisions under Solvency 2 and the statutory financial statements.

| Para.                 | Solvency II value  | Statutory accounts value |
|-----------------------|--|--------------------------|
|                       | C0010  | C0020                    |
| <b>Liabilities</b>    |  |                          |
| R0510                 | Technical provisions – Non-Life  |                          |
| R0520                 | Technical provisions – Non-Life (excluding Health)                                 |                          |
| R0530                 | Technical provisions calculated as a whole   |                          |
| R0540                 | Best Estimate  |                          |
| R0550                 | Risk margin  |                          |
| R0560                 | Technical provisions - Health (similar to Non-Life)                                |                          |
| R0570                 | Technical provisions calculated as a whole   |                          |
| R0580                 | Best Estimate  |                          |
| R0590                 | Risk margin  |                          |
| R0600                 | Technical provisions - Life (excluding index-linked and unit-linked)               |                          |
| R0610                 | Technical provisions - Health (similar to Life)                                    |                          |
| R0620                 | Technical provisions calculated as a whole   |                          |
| R0630                 | Best Estimate  |                          |
| R0640                 | Risk margin  |                          |
| R0650                 | Technical provisions – Life (excluding Health and index-linked and unit-linked)    |                          |
| R0660                 | Technical provisions calculated as a whole   |                          |
| R0670                 | Best Estimate  |                          |
| R0680                 | Risk margin  |                          |
| R0690                 | Technical provisions – index-linked and unit-linked                                |                          |
| R0700                 | Technical provisions calculated as a whole   |                          |
| R0710                 | Best Estimate  |                          |
| R0720                 | Risk margin  |                          |
| <b>Assets</b>         |  |                          |
| R0270                 | Reinsurance recoverables from:   |                          |
| R0280                 | Non-Life and Health similar to Non-Life  |                          |
| R0290                 | Non-Life excluding Health  |                          |
| R0300                 | Health similar to Non-Life   |                          |
| R0310                 | Life and Health similar to Life, excluding Health and index-linked and unit-linked |                          |
| R0320                 | Health similar to Life   |                          |
| R0330                 | Life excluding Health and index-linked and unit-linked                             |                          |
| R0340                 | Life index-linked and unit-linked  |                          |
| <b>Net provisions</b> |  |                          |
| <b>D 2</b>            | <b>26,856,514</b>  | <b>156,143,768</b>       |
|                       | <b>26,856,514</b>  | <b>156,143,768</b>       |
|                       | 0  |                          |
|                       | 22,580,944   |                          |
|                       | 4,275,570  |                          |
|                       | 0  | 0                        |
|                       | 0  |                          |
|                       | 0  |                          |
|                       | 0  |                          |
| <b>D 2</b>            | <b>-10,151,052</b>   | <b>12,910,012</b>        |
|                       | <b>-10,151,052</b>   | <b>12,910,012</b>        |
|                       | 0  |                          |
|                       | -13,888,441  |                          |
|                       | 3,737,390  |                          |
|                       | 0  | 0                        |
|                       | 0  |                          |
|                       | 0  |                          |
|                       | 0  | 0                        |
|                       | 0  |                          |
|                       | 0  |                          |
|                       | 0  |                          |
|                       | 0  |                          |
| <b>D 2</b>            | <b>4,793,857</b>   | <b>26,295,812</b>        |
|                       | <b>4,784,104</b>   | <b>26,295,812</b>        |
|                       | <b>4,784,104</b>   | <b>26,295,812</b>        |
|                       | 0  | 0                        |
|                       | 9,753  | 0                        |
|                       | 9,753  | 0                        |
|                       | 0  | 0                        |
|                       | 0  | 0                        |
|                       | 0  | 0                        |
|                       | 0  | 0                        |
|                       | 11,911,605   | 142,757,968              |

### D.2.1 Bases, methods, and main assumptions

Under Solvency 2, liabilities must be valued at the amount for which they could be transferred between two knowledgeable parties.

Technical Provisions are defined as the sum of a best estimate and a risk margin. The best estimate is the probability weighted mean average of all future cash-flows and the risk margin is the cost of providing the solvency capital required necessary to support these best estimate liabilities.

The following principles were applied for compiling the Solvency 2 technical provisions:

- The liabilities valued in the technical provisions are those associated with existing contracts at the valuation date. Under Solvency 2, contracts must be valued if there is a legal obligation to provide cover even if this is before the commencement date of the policy which is different to the approach under Dutch GAAP.

- The Non-Life business of AEI is split into homogeneous risk groupings referred to as “model points”. These homogeneous risk groups split the business by product and currency and, for significant ones, by program.
- The technical provisions for each model point are calculated using a cash-flow model. This is carried out by predicting the expected cash-flow for each model point separately for each future year until all existing contracts have expired.
- Expenses are projected as for the cash flow projections and allocated between model points and currency and between earned and unearned exposure.
- The best estimate is calculated separately for the premium provision and claim provision. Premium provisions are established in respect of unearned exposure and claims provisions are established in respect of earned exposure.
- Gross cash-flows are calculated separately from reinsurance cash flows, to recognize that there could be significant differences in the timing of these cash flows.
- The assumptions underlying the calculation of the technical provisions are derived based on the assumption that AEI will continue to write new business (going concern assumption).
- A yield curve is required to discount future cash flows. This is the EIOPA provided curve per currency (no VA or MA applied).

#### D.2.2 Level of uncertainty

There are several areas of uncertainty in the calculation of the technical provisions. Reserving is carried out by using standard actuarial methods of projecting the paid (or known) claims to estimate the ultimate claim experience. These methods are generally based on the assumption that the future experience will develop in the same way as historic experience. There is uncertainty in the actual future development patterns, for example due to changes in handling processes such as innovative ways to settle a claim or changes in consumer behaviour.

The main uncertainties concern:

- The number and amount of claims, which can, for example, change because of consumer behaviour, environmental developments or the cost of repair or replacement material.
- Lapse patterns. Generally, the shorter a policy remains in force the lower the income for the company.
- Expense developments. Higher than expected inflation could negatively impact the company's income.

### D.2.3 Differences between Solvency 2 and the statutory financial statements

The below table explains the main differences between statutory and Solvency 2 technical provisions.

|   | Row         | 2024          | 2023          |
|---|-------------|---------------|---------------|
| €'000   |             |               |               |
| Technical provisions per statutory financial statements (Non-Life & Health SLT) |             |               |               |
| Gross   | R0510+R0600 | 169,054       | 161,516       |
| Reinsurance   | R0270       | -26,296       | -25,897       |
| Net   |             | 142,758       | 135,619       |
| Include Net deferred acquisition cost   |             | -55,130       | -44,690       |
| Best estimate loss ratios (Solvency 2 loss ratios)                              |             | -52,390       | -44,562       |
| Reclassification of premiums not yet due  |             | -15,309       | -20,769       |
| Adjustment to best estimate premium provision                                   |             | -385          | 1,675         |
| Best estimate claim handling & maintenance expenses                             |             | 9,342         | 9,918         |
| Inclusion of Non-Life future cashflow   |             | -3,859        | -3,434        |
| Inclusion of Health SLT future cashflow   |             | -29,329       | -29,282       |
| Discounting   |             | 1,973         | 1,347         |
| Risk Margin   |             | 8,013         | 8,586         |
| Profit share on future risk expiry  |             | 6,591         | 3,723         |
| Reclassification of inventory held for claims fulfilment                        |             | -363          | -516          |
| Miscellaneous   |             | -             | 6             |
|   |             | -130,846      | -117,998      |
| Gross technical provisions  | R0510+R0600 | 16,705        | 25,441        |
| Reinsurers' share of technical provisions                                       | R0270       | -4,794        | -7,820        |
| <b>Net technical provisions per Solvency 2</b>                                  |             | <b>11,912</b> | <b>17,621</b> |

#### D.2.3.1 Premium and claims provision

The methodology for the calculation of the premium provision for the Non-Life business, in AEI, under Solvency 2 is fundamentally different to that used in the financial statements. The premium provision is based on the probability weighted average of future cash flows related to policies within contract boundaries, whereas under Dutch GAAP, the unearned premium reserve is an allocation of premium income to the remaining time to expiry of the insurance contracts already issued. Though not directly comparable, the main difference arises due to the recognition of profit on issued policies and expected profit in future premiums.

#### D.2.3.2 Risk Margin

For Solvency 2, a risk margin is determined using a cost of capital approach which involves calculating the cost of holding the SCR per Standard formula calculation at each future time period until the technical provisions at the reporting date have run off. The amounts are then discounted back to the current time period. The calculation excludes new business and market risk. AEI determines its risk margin by projecting the SCR in line with the run-off of best estimate liabilities (method 2).

### D.2.3.3 Discounting

Under Solvency 2 the best estimate technical provisions are discounted rather than at nominal value under Dutch GAAP.

### D.2.4 Use of Long-term guarantee package

- AEI has not applied the matching adjustment referred to in Article 77b of Directive 2009/138/EC.
- AEI has not used the volatility adjustment referred to in Article 77d of Directive 2009/138/EC
- AEI has not applied the transitional risk-free interest rate-term structure referred to in Article 308c of Directive 2009/138/EC.
- AEI has not applied the transitional deduction referred to in Article 308d of Directive 2009/138/EC.

### D.2.5 Reinsurance

Reinsurance recoverables represent the net discounted cash flow expected to be received from AEI's reinsurers. AEI only uses facultative reinsurance, primarily quota share, to cede risk on particular programs, either due to the business being outside of risk appetite or because program commercials so require.

### D.2.6 Material changes in the relevant assumptions made in the calculation of technical provisions

No material changes were made compared to the prior period.

## D.3 Other liabilities

The following table shows the other liabilities as per 31 December.

|                                   | Row   | Solvency 2    | Statutory     |
|-----------------------------------|-------|---------------|---------------|
| €'000                             |       |               |               |
| Deferred tax liabilities          | R0780 | 14,999        | -             |
| Insurance & intermediary payables | R0820 | 13,225        | 13,225        |
| Reinsurance payables              | R0830 | 25,063        | 25,063        |
| Payables (trade)                  | R0840 | 20,241        | 22,369        |
| <b>Other liabilities</b>          |       | <b>73,528</b> | <b>60,657</b> |

### D.3.1 Deferred tax liabilities

The deferred taxes shown in the below table comprises net deferred tax liabilities on the temporary valuation differences between the statutory financial statements and Solvency 2.

|   | Row          | 2024          |
|---|--------------|---------------|
| €'000   |              |               |
| Deferred tax asset out of losses carried forward      | R0040        | -             |
| Deferred tax liabilities out of valuation differences | R0780        | 14,999        |
| <b>Total deferred tax liabilities</b>                 | <b>R0780</b> | <b>14,999</b> |

### D.3.2 Insurance and Intermediaries payables

Insurance and intermediary payables are measured at the undiscounted amount of the cash or other consideration expected to be paid.

### D.3.3 Reinsurance payables

Reinsurance payables are measured at the undiscounted amount of the cash or other consideration expected to be paid.

### D.3.4 Trade Payables

Deferred reinsurance commissions are valued at nil under Solvency 2.

|  | Row          | 2024          |
|--|--------------|---------------|
| €'000  |              |               |
| Payables (trade, not insurance) statutory value                      | R0840        | 22,369        |
| IPT due on Premiums not yet due reclassified to Technical provisions | R0510        | -2,128        |
| <b>Payables (trade, not insurance) in Solvency 2</b>                 | <b>R0840</b> | <b>20,241</b> |

## D.4 Alternative methods for valuation

No alternative methods of valuation were used.

## D.5 Any other disclosures

None.

## E Capital management

### E.1 Own funds

#### E.1.1 Capital Management Policy

AEI's Capital Management policy, which is approved by the Board of Directors and the Supervisory Board, describes the company's internal capital targets. Besides the aim to always fulfil regulatory capital requirements, the company has also determined internal buffers on top of that regulatory capital.

#### E.1.2 Analysis of Own Funds

The table below provides an overview of movements in and composition of Own funds.

|   | 31-Dec-23     | Mvmt in year   | Transfers | 31-Dec-24     |
|---|---------------|----------------|-----------|---------------|
| €'000   |               |                |           |               |
| <b>Tier 1:</b>  |               |                |           |               |
| Share capital   | 43,600        | -9,156         | -         | 34,444        |
| Share premium reserve                                   | 15,767        | -15,767        | -         | -             |
| Total ordinary share capital                            | 59,367        | -24,923        | -         | 34,444        |
| Reconciliation reserve before deductions                | 40,419        | 14,177         | -         | 54,596        |
| Foreseeable dividends                                   | -             | -              | -         | -             |
| Restricted own funds (ring fenced funds)                | -             | -              | -         | -             |
| Total reconciliation reserve                            | 40,419        | 14,177         | -         | 54,596        |
| Deductions for participations in financial institutions | -             | -              | -         | -             |
| <b>Total tier 1 own funds after deductions</b>          | <b>99,786</b> | <b>-10,746</b> | <b>-</b>  | <b>89,040</b> |
| <b>Eligible own funds to cover SCR:</b>                 |               |                |           |               |
| Tier 1  | 99,786        | -10,746        | 0         | 89,040        |
| Tier 2  | 0             | 0              | 0         | 0             |
| Tier 3  | 0             | 0              | 0         | 0             |
|   | <b>99,786</b> | <b>-10,746</b> | <b>0</b>  | <b>89,040</b> |
| SCR   | 41,534        | 630            |           | 42,164        |
| <b>Solvency ratio</b>                                   | <b>240%</b>   | <b>-29%</b>    |           | <b>211%</b>   |

### E.1.3 Differences between equity in the statutory financial statements and excess of assets over liabilities as calculated for solvency purposes

The main differences between equity as shown in the company financial statements and the excess of assets over liabilities as calculated for solvency purposes are shown in the following table.

|  | Row         | Statutory | Solvency 2 | 2023          |
|--|-------------|-----------|------------|---------------|
| €'000  |             |           |            |               |
| Shareholders' equity in the statutory financial statements                     |             |           |            | 44,508        |
| Derecognition of deferred acquisition costs                                    | R0020       | 61,819    | -          | -61,819       |
| Derecognition of deferred reinsurance commission                               | R0840       | -6,688    | -          | 6,688         |
| Valuation differences C.I.U.   | R0180       | 7,936     | 8,091      | 154           |
| Valuation differences gross best estimate (*)                                  | R0510&R0600 | -169,054  | -17,774    | 151,280       |
| Valuation differences reinsurance best estimate                                | R0270       | 26,296    | 4,794      | -21,502       |
| Valuation differences gross best estimate - profit share on future risk expiry | R0510&R0600 | -         | -6,591     | -6,591        |
| Risk margin on gross best estimate - Non-Life                                  | R0550       | -         | -4,276     | -4,276        |
| Risk margin on gross best estimate - Health SLT                                | R0640       | -         | -3,737     | -3,737        |
| Prepayments  |             | 183       | -          | -183          |
| Deferred tax asset on Net Operating Losses                                     |             | 485       | -          | -485          |
| Deferred tax liabilities on valuation differences                              | R0040&R0780 | -         | -14,999    | -14,999       |
|  |             |           |            | <u>44,532</u> |
| <b>Own funds in Schedule 02.01</b>   |             |           |            | <b>89,040</b> |

(\*) After reclassification of premiums and commissions not yet due to technical provisions.

### E.1.3 Items deducted from Own Funds

No items require deduction of Own funds.



## E.2 Solvency Capital Requirement and Minimum Capital Requirement

The SCR as at 31 December amounts to:

|   | 2024          | 2023          |
|---|---------------|---------------|
| €'000                                     |               |               |
| Market Risk                               | 7,671         | 10,192        |
| Counterparty Default Risk                 | 6,888         | 6,664         |
| Non-Life Underwriting Risk                | 41,299        | 37,528        |
| Life Underwriting Risk                    | -             | -             |
| Health Underwriting Risk                  | 11,795        | 11,100        |
| Sum of risk modules                       | <b>67,653</b> | <b>65,484</b> |
| Diversification between risk modules      | -17,591       | -18,064       |
| Basic SCR                                 | <b>50,062</b> | <b>47,420</b> |
| Operational Risk                          | 6,763         | 6,019         |
| Loss-absorbing capacity of deferred taxes | -14,661       | -11,905       |
| <b>SCR</b>                                | <b>42,164</b> | <b>41,534</b> |

No undertaking specific parameters or simplifications are applied. No capital add-ons have been imposed by the DNB.

The MCR has been calculated using the linear calculation as set out in the Solvency 2 Directive.

|                                    | Row          | 2024          | 2023          |
|------------------------------------|--------------|---------------|---------------|
| €'000                              |              |               |               |
| Linear MCR                         | R0300        | 14,783        | 15,310        |
| SCR                                | R0310        | 42,164        | 41,534        |
| MCR cap                            | R0320        | 18,974        | 18,690        |
| MCR floor                          | R0330        | 10,541        | 10,383        |
| Combined MCR                       | R0340        | 14,783        | 15,310        |
| Absolute floor of the MCR          | R0350        | 4,000         | 4,000         |
| <b>Minimum Capital Requirement</b> | <b>R0400</b> | <b>14,783</b> | <b>13,038</b> |

Details of the SCR and MCR calculations, including the MCR inputs and floor, are provided in the appended S.25.01 and S.28.01.

## E.3 Use of the duration-based equity risk sub-module in the calculation of the Solvency Capital Requirement

The company does not make use of the duration-based equity risk sub-module in the calculation of the SCR.

#### **E.4 Differences between the standard formula and any internal models used**

The company does not use an internal model.

#### **E.5 Non-compliance with the minimum capital requirement and significant non-compliance with the solvency capital requirement**

The Company has met its SCR and MCR at all times during the year.

#### **E.6 Any other disclosures**

There is no other information regarding the capital management of the Company that is deemed material to report.

## F Quantitative reporting templates

| <b>P.02.01.02 – Balance sheet</b> |  | <b>Solvency II value</b> |
|-----------------------------------|--|--------------------------|
|                                   | <b>Assets</b>  | <b>C0010</b>             |
| R0030                             | Intangible assets  | 0                        |
| R0040                             | Deferred tax assets  | 0                        |
| R0050                             | Pension benefit surplus  | 0                        |
| R0060                             | Property, plant & equipment held for own use   | 0                        |
| R0070                             | Investments (other than assets held for index-linked and unit-linked contracts)        | 101,860                  |
| R0080                             | Property (other than for own use)  | 0                        |
| R0090                             | Holdings in related undertakings, including participations                             | 0                        |
| R0100                             | Equities   | 0                        |
| R0110                             | Equities - listed  | 0                        |
| R0120                             | Equities - unlisted  | 0                        |
| R0130                             | Bonds  | 85,234                   |
| R0140                             | Government Bonds   | 11,731                   |
| R0150                             | Corporate Bonds  | 73,503                   |
| R0160                             | Structured notes   | 0                        |
| R0170                             | Collateralised securities  | 0                        |
| R0180                             | Collective Investments Undertakings  | 16,626                   |
| R0190                             | Derivatives  | 0                        |
| R0200                             | Deposits other than cash equivalents   | 0                        |
| R0210                             | Other investments  | 0                        |
| R0220                             | Assets held for index-linked and unit-linked contracts                                 | 0                        |
| R0230                             | Loans and mortgages  | 0                        |
| R0240                             | Loans on policies  | 0                        |
| R0250                             | Loans and mortgages to individuals   | 0                        |
| R0260                             | Other loans and mortgages  | 0                        |
| R0270                             | Reinsurance recoverables from:   | 4,794                    |
| R0280                             | Non-life and health similar to non-life  | 4,784                    |
| R0290                             | Non-life excluding health  | 4,784                    |
| R0300                             | Health similar to non-life   | 0                        |
| R0310                             | Life and health similar to life, excluding health and index-linked and unit-linked     | 10                       |
| R0320                             | Health similar to life   | 10                       |
| R0330                             | Life excluding health and index-linked and unit-linked                                 | 0                        |
| R0340                             | Life index-linked and unit-linked  | 0                        |
| R0350                             | Deposits to cedants  | 0                        |
| R0360                             | Insurance and intermediaries receivables   | 60,770                   |
| R0370                             | Reinsurance receivables  | 0                        |
| R0380                             | Receivables (trade, not insurance)   | 7,530                    |
| R0390                             | Own shares (held directly)   | 0                        |
| R0400                             | Amounts due in respect of own fund items or initial fund called up but not yet paid in | 0                        |
| R0410                             | Cash and cash equivalents  | 4,319                    |
| R0420                             | Any other assets, not elsewhere shown  | 0                        |
| R0500                             | <b>Total assets</b>  | <b>179,273</b>           |

|       |   | <b>Solvency II<br/>value</b> |
|-------|---|------------------------------|
|       |   | C0010                        |
| R0510 | <b>Liabilities</b>  |                              |
|       | Technical provisions – non-life   | 26,857                       |
| R0520 | Technical provisions – non-life (excluding health)                              | 26,857                       |
| R0530 | TP calculated as a whole  | 0                            |
| R0540 | Best Estimate   | 22,581                       |
| R0550 | Risk margin   | 4,276                        |
| R0560 | Technical provisions - health (similar to non-life)                             | 0                            |
| R0570 | TP calculated as a whole  | 0                            |
| R0580 | Best Estimate   | 0                            |
| R0590 | Risk margin   | 0                            |
| R0600 | Technical provisions - life (excluding index-linked and unit-linked)            | -10,151                      |
| R0610 | Technical provisions - health (similar to life)                                 | -10,151                      |
| R0620 | TP calculated as a whole  | 0                            |
| R0630 | Best Estimate   | -13,888                      |
| R0640 | Risk margin   | 3,737                        |
| R0650 | Technical provisions – life (excluding health and index-linked and unit-linked) | 0                            |
| R0660 | TP calculated as a whole  | 0                            |
| R0670 | Best Estimate   | 0                            |
| R0680 | Risk margin   | 0                            |
| R0690 | Technical provisions – index-linked and unit-linked                             | 0                            |
| R0700 | TP calculated as a whole  | 0                            |
| R0710 | Best Estimate   | 0                            |
| R0720 | Risk margin   | 0                            |
| R0740 | Contingent liabilities  | 0                            |
| R0750 | Provisions other than technical provisions                                      | 0                            |
| R0760 | Pension benefit obligations   | 0                            |
| R0770 | Deposits from reinsurers  | 0                            |
| R0780 | Deferred tax liabilities  | 14,999                       |
| R0790 | Derivatives   | 0                            |
| R0800 | Debts owed to credit institutions   | 0                            |
| R0810 | Financial liabilities other than debts owed to credit institutions              | 0                            |
| R0820 | Insurance & intermediaries payables   | 13,225                       |
| R0830 | Reinsurance payables  | 25,063                       |
| R0840 | Payables (trade, not insurance)   | 20,241                       |
| R0850 | Subordinated liabilities  | 0                            |
| R0860 | Subordinated liabilities not in Basic Own Funds                                 | 0                            |
| R0870 | Subordinated liabilities in Basic Own Funds                                     | 0                            |
| R0880 | Any other liabilities, not elsewhere shown                                      | 0                            |
| R0900 | <b>Total liabilities</b>  | 90,234                       |
| R1000 | <b>Excess of assets over liabilities</b>  | 89,040                       |



**P.05.01.02.01 – Premiums, claims and expenses by line of business**

|  |
|--|
| <b>Premiums written</b>                                |
| R0110 Gross - Direct Business                          |
| R0120 Gross - Proportional reinsurance accepted        |
| R0130 Gross - Non-proportional reinsurance accepted    |
| R0140 Reinsurers' share                                |
| R0200 Net  |
| <b>Premiums earned</b>                                 |
| R0210 Gross - Direct Business                          |
| R0220 Gross - Proportional reinsurance accepted        |
| R0230 Gross - Non-proportional reinsurance accepted    |
| R0240 Reinsurers' share                                |
| R0300 Net  |
| <b>Claims incurred</b>                                 |
| R0310 Gross - Direct Business                          |
| R0320 Gross - Proportional reinsurance accepted        |
| R0330 Gross - Non-proportional reinsurance accepted    |
| R0340 Reinsurers' share                                |
| R0400 Net  |
| R0550 <b>Expenses incurred</b>                         |
| R1210 <b>Balance - other technical expenses/income</b> |
| R1300 <b>Total technical expenses</b>                  |

| Line of Business for: non-life insurance and reinsurance obligations (direct business and accepted proportional reinsurance) |                              | Total   |
|--|------------------------------|---------|
| Fire and other damage to property insurance  | Miscellaneous financial loss |         |
| C0070  | C0120                        | C0200   |
| 212,646  | 17,123                       | 229,769 |
| 0  | 0                            | 0       |
| 89,435   | 737                          | 90,171  |
| 123,211  | 16,386                       | 139,597 |
| 193,349  | 24,155                       | 217,504 |
| 0  | 0                            | 0       |
| 86,552   | 2,625                        | 89,177  |
| 106,798  | 21,529                       | 128,327 |
| 42,056   | 3,452                        | 45,508  |
| 0  | 0                            | 0       |
| 19,861   | 704                          | 20,565  |
| 22,195   | 2,748                        | 24,943  |
| 83,388   | 16,478                       | 99,866  |
|  |                              | 0       |
|  |                              | 99,866  |

|  |
|--|
| <b>Premiums written</b>                                |
| R1410 Gross  |
| R1420 Reinsurers' share                                |
| R1500 Net  |
| <b>Premiums earned</b>                                 |
| R1510 Gross  |
| R1520 Reinsurers' share                                |
| R1600 Net  |
| <b>Claims incurred</b>                                 |
| R1610 Gross  |
| R1620 Reinsurers' share                                |
| R1700 Net  |
| R1900 <b>Expenses incurred</b>                         |
| R2510 <b>Balance - other technical expenses/income</b> |
| R2600 <b>Total expenses</b>                            |
| R2700 <b>Total amount of surrenders</b>                |

| Line of Business for: life insurance obligations | Total |       |
|--|-------|-------|
| Health insurance                                 | C0210 | C0300 |
|  | 5,890 | 5,890 |
|  | 96    | 96    |
|  | 5,794 | 5,794 |
|  | 5,933 | 5,933 |
|  | 101   | 101   |
|  | 5,832 | 5,832 |
|  | 780   | 780   |
|  | 12    | 12    |
|  | 768   | 768   |
|  | 2,749 | 2,749 |
|  |       | 0     |
|  |       | 2,749 |
|  | 0     | 0     |

**P.12.01.02 – Life and Health SLT Technical Provisions**

|       |   |
|-------|---|
| R0010 | <b>Technical provisions calculated as a whole</b>   |
| R0020 | <b>Total Recoverables from reinsurance/SPV and Finite Re</b> after the adjustment for expected losses due to counterparty default associated to TP as a whole |
|       | <b>Technical provisions calculated as a sum of BE and RM</b>  |
|       | <b>Best Estimate</b>  |
| R0030 | <b>Gross Best Estimate</b>  |
| R0080 | Total Recoverables from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default                                    |
| R0090 | Best estimate minus recoverables from reinsurance/SPV and Finite Re - total   |
| R0100 | <b>Risk Margin</b>  |
| R0200 | <b>Technical provisions - total</b>   |

| Health insurance (direct business)       |                                      |         | Total (Health similar to life insurance) |
|--|--------------------------------------|---------|--|
| Contracts without options and guarantees | Contracts with options or guarantees |         |  |
| C0160                                    | C0170                                | C0180   | C0210                                    |
| 0  |                                      |         | 0  |
| 0  |                                      | 0       |  |
|  |                                      |         |  |
|  | -13,888                              | -13,888 |  |
|  | 10                                   | 10      |  |
|  | -13,898                              | -13,898 |  |
| 3,737                                    |                                      |         | 3,737                                    |
| -10,151                                  |                                      |         | -10,151                                  |

**P.17.01.02 – Non-Life Technical Provisions**

|       |  |
|-------|--|
| R0010 | <b>Technical provisions calculated as a whole</b>  |
| R0050 | Total Recoverables from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default associated to TP as a whole |
|       | <b>Technical provisions calculated as a sum of BE and RM</b>   |
|       | <b>Best estimate</b>   |
|       | Premium provisions   |
| R0060 | Gross  |
| R0140 | Total recoverable from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default                              |
| R0150 | Net Best Estimate of Premium Provisions  |
|       | <b>Claims provisions</b>   |
| R0160 | Gross  |
| R0240 | Total recoverable from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default                              |
| R0250 | Net Best Estimate of Claims Provisions   |
| R0260 | <b>Total Best estimate - gross</b>   |
| R0270 | <b>Total Best estimate - net</b>   |
| R0280 | <b>Risk margin</b>   |
|       | <b>Technical provisions - total</b>  |
| R0320 | Technical provisions - total   |
| R0330 | Recoverable from reinsurance contract/SPV and Finite Re after the adjustment for expected losses due to counterparty default - total                   |
| R0340 | Technical provisions minus recoverables from reinsurance/SPV and Finite Re - total   |

| Direct business and accepted proportional reinsurance |                              | Total Non-Life obligation |
|---|------------------------------|---------------------------|
| Fire and other damage to property insurance           | Miscellaneous financial loss |                           |
| C0080   | C0130                        | C0180                     |
| 0   | 0                            | 0                         |
| 0   | 0                            | 0                         |
|   |                              |                           |
|   |                              |                           |
| 4,260   | 11,712                       | 15,973                    |
| 1,659   | 716                          | 2,375                     |
| 2,601   | 10,996                       | 13,598                    |
|   |                              |                           |
| 5,889   | 719                          | 6,608                     |
| 2,022   | 388                          | 2,410                     |
| 3,868   | 331                          | 4,199                     |
| 10,149  | 12,432                       | 22,581                    |
| 6,469   | 11,328                       | 17,797                    |
| 2,907   | 1,368                        | 4,276                     |
|   |                              |                           |
| 13,057  | 13,800                       | 26,857                    |
| 3,680   | 1,104                        | 4,784                     |
| 9,376   | 12,696                       | 22,072                    |



**P.19.01.21 - Non-life Insurance Claims Information (simplified template for the public disclosure)**

**Total Non-Life Business**

|       |                                   |              |                    |
|-------|-----------------------------------|--------------|--------------------|
| Z0020 | Accident year / Underwriting year | <b>Z0020</b> | Accident year [AY] |
|-------|-----------------------------------|--------------|--------------------|

**Gross Claims Paid (non-cumulative)**  
(absolute amount)

| Year         | Development year |        |       |       |       |       |       |       |       |       |        | In Current year | Sum of years (cumulative) |         |   |
|--------------|------------------|--------|-------|-------|-------|-------|-------|-------|-------|-------|--------|-----------------|---------------------------|---------|---|
|              | 0                | 1      | 2     | 3     | 4     | 5     | 6     | 7     | 8     | 9     | 10 & + |                 |                           |         |   |
|              | C0010            | C0020  | C0030 | C0040 | C0050 | C0060 | C0070 | C0080 | C0090 | C0100 | C0110  |                 |                           |         |   |
| R0100        | Prior            |        |       |       |       |       |       |       |       |       |        |                 |                           |         |   |
| R0160        | N-9              | 0      | 0     | 0     | 0     | 0     | 0     | 59    | 0     | 0     | 0      | 0               | 0                         | 0       | 0 |
| R0170        | N-8              | 0      | 0     | 0     | 0     | 0     | 60    | 0     | 0     | 0     | 0      | 0               | 0                         | 0       | 0 |
| R0180        | N-7              | 0      | 0     | 0     | 4     | 61    | 0     | 2     | 0     | 0     | 0      | 0               | 0                         | 0       | 0 |
| R0190        | N-6              | 0      | 0     | 9     | 64    | 2     | 10    | 0     | 0     | 0     | 0      | 0               | 0                         | 0       | 0 |
| R0200        | N-5              | 0      | 535   | 819   | 11    | 0     | 0     | 0     | 0     | 0     | 0      | 0               | 0                         | 0       | 0 |
| R0210        | N-4              | 8,787  | 5,403 | 53    | 5     | 0     | 0     | 0     | 0     | 0     | 0      | 0               | 0                         | 0       | 0 |
| R0220        | N-3              | 43,173 | 7,545 | 67    | 0     | 0     | 0     | 0     | 0     | 0     | 0      | 0               | 0                         | 0       | 0 |
| R0230        | N-2              | 36,890 | 6,230 | 157   | 0     | 0     | 0     | 0     | 0     | 0     | 0      | 0               | 0                         | 0       | 0 |
| R0240        | N-1              | 40,281 | 7,640 | 0     | 0     | 0     | 0     | 0     | 0     | 0     | 0      | 0               | 0                         | 0       | 0 |
| R0250        | N                | 38,835 | 0     | 0     | 0     | 0     | 0     | 0     | 0     | 0     | 0      | 0               | 0                         | 0       | 0 |
| R0260        |                  |        |       |       |       |       |       |       |       |       |        |                 |                           |         |   |
| <b>Total</b> |                  |        |       |       |       |       |       |       |       |       |        |                 | 46,632                    | 196,700 |   |

**Gross undiscounted Best Estimate Claims Provisions**  
(absolute amount)

| Year         | Development year |        |       |       |       |       |       |       |       |       |        | Year end (discounted data) |       |   |   |
|--------------|------------------|--------|-------|-------|-------|-------|-------|-------|-------|-------|--------|----------------------------|-------|---|---|
|              | 0                | 1      | 2     | 3     | 4     | 5     | 6     | 7     | 8     | 9     | 10 & + |                            |       |   |   |
|              | C0200            | C0210  | C0220 | C0230 | C0240 | C0250 | C0260 | C0270 | C0280 | C0290 | C0300  |                            |       |   |   |
| R0100        | Prior            |        |       |       |       |       |       |       |       |       |        |                            |       |   |   |
| R0160        | N-9              | 0      | 0     | 0     | 0     | 0     | 2     | 65    | 1     | 0     | 0      | 0                          | 0     | 0 | 0 |
| R0170        | N-8              | 0      | 0     | 0     | 0     | 7     | 113   | 1     | 1     | 0     | 0      | 0                          | 0     | 0 | 0 |
| R0180        | N-7              | 0      | 0     | 0     | 34    | 139   | 2     | 1     | 0     | 0     | 0      | 0                          | 0     | 0 | 0 |
| R0190        | N-6              | 0      | 0     | 118   | 135   | 2     | 1     | 0     | 0     | 0     | 0      | 0                          | 0     | 0 | 0 |
| R0200        | N-5              | 0      | 247   | 57    | 7     | 1     | 0     | 0     | 0     | 0     | 0      | 0                          | 0     | 0 | 0 |
| R0210        | N-4              | 12,288 | 150   | 41    | 3     | 0     | 0     | 0     | 0     | 0     | 0      | 0                          | 0     | 0 | 0 |
| R0220        | N-3              | 9,473  | 177   | 13    | 0     | 0     | 0     | 0     | 0     | 0     | 0      | 0                          | 0     | 0 | 0 |
| R0230        | N-2              | 8,213  | 346   | 15    | 0     | 0     | 0     | 0     | 0     | 0     | 0      | 0                          | 0     | 0 | 0 |
| R0240        | N-1              | 7,565  | 235   | 0     | 0     | 0     | 0     | 0     | 0     | 0     | 0      | 0                          | 0     | 0 | 0 |
| R0250        | N                | 6,548  | 0     | 0     | 0     | 0     | 0     | 0     | 0     | 0     | 0      | 0                          | 0     | 0 | 0 |
| R0260        |                  |        |       |       |       |       |       |       |       |       |        |                            |       |   |   |
| <b>Total</b> |                  |        |       |       |       |       |       |       |       |       |        |                            | 6,608 |   |   |



**P.23.01.01 - Own funds**
**Basic own funds before deduction for participations in other financial sector as foreseen in article 68 of Delegated Regulation 2015/35**

|       |   |
|-------|---|
| R0010 | Ordinary share capital (gross of own shares)  |
| R0030 | Share premium account related to ordinary share capital   |
| R0040 | Initial funds, members' contributions or the equivalent basic own - fund item for mutual and mutual-type undertakings |
| R0050 | Subordinated mutual member accounts   |
| R0070 | Surplus funds   |
| R0090 | Preference shares   |
| R0110 | Share premium account related to preference shares  |
| R0130 | Reconciliation reserve  |
| R0140 | Subordinated liabilities  |
| R0160 | An amount equal to the value of net deferred tax assets   |
| R0180 | Other own fund items approved by the supervisory authority as basic own funds not specified above                     |

**Own funds from the financial statements that should not be represented by the reconciliation reserve and do not meet the criteria to be classified as Solvency II own funds**

|       |   |
|-------|---|
| R0220 | Own funds from the financial statements that should not be represented by the reconciliation reserve and do not meet the criteria to be classified as Solvency II own funds |
|-------|---|

**Deductions**

|       |  |
|-------|--|
| R0230 | Deductions for participations in financial and credit institutions |
|-------|--|

**Total basic own funds after deductions**
**Ancillary own funds**

|       |   |
|-------|---|
| R0300 | Unpaid and uncalled ordinary share capital callable on demand   |
| R0310 | Unpaid and uncalled initial funds, members' contributions or the equivalent basic own fund item for mutual and mutual - type undertakings, callable on demand |
| R0320 | Unpaid and uncalled preference shares callable on demand  |
| R0330 | A legally binding commitment to subscribe and pay for subordinated liabilities on demand  |
| R0340 | Letters of credit and guarantees under Article 96(2) of the Directive 2009/138/EC   |
| R0350 | Letters of credit and guarantees other than under Article 96(2) of the Directive 2009/138/EC  |
| R0360 | Supplementary members calls under first subparagraph of Article 96(3) of the Directive 2009/138/EC  |
| R0370 | Supplementary members calls - other than under first subparagraph of Article 96(3) of the Directive 2009/138/EC   |
| R0390 | Other ancillary own funds   |
| R0400 | <b>Total ancillary own funds</b>  |

**Available and eligible own funds**

|       |   |
|-------|---|
| R0500 | Total available own funds to meet the SCR |
| R0510 | Total available own funds to meet the MCR |
| R0540 | Total eligible own funds to meet the SCR  |
| R0550 | Total eligible own funds to meet the MCR  |

**SCR**
**MCR**
**Ratio of Eligible own funds to SCR**
**Ratio of Eligible own funds to MCR**

| Total  | Tier 1 - unrestricted | Tier 1 - restricted | Tier 2 | Tier 3 |
|--------|-----------------------|---------------------|--------|--------|
| C0010  | C0020                 | C0030               | C0040  | C0050  |
|        |                       |                     |        |        |
| 34,444 | 34,444                | 0                   | 0      |        |
| 0      | 0                     |                     | 0      |        |
| 0      | 0                     |                     | 0      |        |
| 0      |                       | 0                   | 0      | 0      |
| 0      | 0                     |                     |        |        |
| 0      |                       | 0                   | 0      | 0      |
| 54,596 | 54,596                |                     |        |        |
| 0      |                       | 0                   | 0      | 0      |
| 0      |                       |                     |        | 0      |
| 0      | 0                     | 0                   | 0      | 0      |
| 89,040 | 89,040                | 0                   | 0      | 0      |
| 0      |                       |                     | 0      |        |
| 0      |                       |                     | 0      |        |
| 0      |                       |                     | 0      | 0      |
| 0      |                       |                     | 0      | 0      |
| 0      |                       |                     | 0      | 0      |
| 0      |                       |                     | 0      | 0      |
| 0      |                       |                     | 0      | 0      |
| 0      |                       |                     | 0      | 0      |
| 89,040 | 89,040                | 0                   | 0      | 0      |
| 89,040 | 89,040                | 0                   | 0      |        |
| 89,040 | 89,040                | 0                   | 0      | 0      |
| 89,040 | 89,040                | 0                   | 0      |        |
| 42,163 |                       |                     |        |        |
| 14,783 |                       |                     |        |        |
| 2.1118 |                       |                     |        |        |
| 6.0233 |                       |                     |        |        |



**Reconciliation reserve**  
 R0700 Excess of assets over liabilities  
 R0710 Own shares (held directly and indirectly)  
 R0720 Foreseeable dividends, distributions and charges  
 R0730 Other basic own fund items  
 R0740 Adjustment for restricted own fund items in respect of matching adjustment portfolios and ring fenced funds  
 R0760 **Reconciliation reserve**  
**Expected profits**  
 R0770 Expected profits included in future premiums (EPIFP) - Life business  
 R0780 Expected profits included in future premiums (EPIFP) - Non- life business  
 R0790 **Total Expected profits included in future premiums (EPIFP)**

| C0060  |   |  |  |  |
|--------|---|--|--|--|
| 89,040 | - |  |  |  |
| 0      | - |  |  |  |
| 0      | - |  |  |  |
| 34,444 | - |  |  |  |
| 0      | - |  |  |  |
| 54,596 | - |  |  |  |
|        | - |  |  |  |
| 27,552 | - |  |  |  |
| 14,232 | - |  |  |  |
| 41,784 | - |  |  |  |

**P.25.01.21 - Solvency Capital Requirement - for undertakings on Standard Formula**

|       |   | <b>Gross solvency capital requirement</b> |
|-------|---|---|
|       |   | C0110                                     |
| R0010 | Market risk                               | 7,671                                     |
| R0020 | Counterparty default risk                 | 6,888                                     |
| R0030 | Life underwriting risk                    | 0   |
| R0040 | Health underwriting risk                  | 11,795                                    |
| R0050 | Non-life underwriting risk                | 41,299                                    |
| R0060 | Diversification                           | -17,591                                   |
| R0070 | Intangible asset risk                     | 0   |
| R0100 | <b>Basic Solvency Capital Requirement</b> | <b>50,062</b>                             |

**Calculation of Solvency Capital Requirement**

|                                 |   |               |
|---------------------------------|---|---------------|
| R0130                           | Operational risk  | 6,762         |
| R0140                           | Loss-absorbing capacity of technical provisions   | 0             |
| R0150                           | Loss-absorbing capacity of deferred taxes   | -14,661       |
| R0160                           | Capital requirement for business operated in accordance with Art. 4 of Directive 2003/41/EC | 0             |
| R0200                           | <b>Solvency capital requirement excluding capital add-on</b>                                | <b>42,163</b> |
| R0210                           | Capital add-on already set  | 0             |
| R0211                           | of which, capital add-ons already set - Article 37 (1) Type a                               | 0             |
| R0212                           | of which, capital add-ons already set - Article 37 (1) Type b                               | 0             |
| R0213                           | of which, capital add-ons already set - Article 37 (1) Type c                               | 0             |
| R0214                           | of which, capital add-ons already set - Article 37 (1) Type d                               | 0             |
| R0220                           | <b>Solvency capital requirement</b>   | <b>42,163</b> |
| <b>Other information on SCR</b> |   |               |
| R0400                           | Capital requirement for duration-based equity risk sub-module                               | 0             |
| R0410                           | Total amount of Notional Solvency Capital Requirement for remaining part                    | 0             |
| R0420                           | Total amount of Notional Solvency Capital Requirements for ring fenced funds                | 0             |
| R0430                           | Total amount of Notional Solvency Capital Requirement for matching adjustment portfolios    | 0             |
| R0440                           | Diversification effects due to RFF nSCR aggregation for article 304                         | 0             |

**Approach to tax rate**

|       |                                    | <b>Yes/No</b> |
|-------|------------------------------------|---------------|
|       |                                    | C0109         |
| R0590 | Approach based on average tax rate | 2 - No        |

**Calculation of loss absorbing capacity of deferred taxes**

|       |  | <b>LAC DT</b> |
|-------|--|---------------|
|       |  | C0130         |
| R0600 | DTA  |               |
| R0610 | DTA carry forward  |               |
| R0620 | DTA due to deductible temporary differences                              |               |
| R0630 | DTL  |               |
| R0640 | LAC DT   | -14,661       |
| R0650 | LAC DT justified by reversion of deferred tax liabilities                | -14,661       |
| R0660 | LAC DT justified by reference to probable future taxable economic profit | 0             |
| R0670 | LAC DT justified by carry back, current year                             | 0             |
| R0680 | LAC DT justified by carry back, future years                             | 0             |
| R0690 | Maximum LAC DT   | -14,661       |

**P.28.01.01 - Minimum Capital Requirement - Only life or only non-life insurance or reinsurance activity**
**Linear formula component for non-life insurance and reinsurance obligations**

|       |  | C0010   |   |
|-------|--|---|---|
|       |  | Net (of reinsurance/SPV) best estimate and TP calculated as a whole | Net (of reinsurance) written premiums in the last 12 months |
| R0010 | MCRNL Result   |   |   |
| R0080 | Fire and other damage to property insurance and proportional reinsurance | C0020<br>6,469  | C0030<br>123,211  |
| R0130 | Miscellaneous financial loss insurance and proportional reinsurance      | 11,238  | 16,386  |

**Linear formula component for life insurance and reinsurance obligations**

|       |   | C0040   |  |
|-------|---|---|--|
|       |   | Net (of reinsurance/SPV) best estimate and TP calculated as a whole | Net (of reinsurance/SPV) total capital at risk |
| R0200 | MCRL Result   |   |  |
| R0240 | Other life (re)insurance and health (re)insurance obligations | C0050   | C0060  |
| R0250 | Total capital at risk for all life (re)insurance obligations  |   | 1,182,319                                      |

**Overall MCR calculation**

|       | C0070                              |
|-------|------------------------------------|
| R0300 | Linear MCR                         |
| R0310 | SCR                                |
| R0320 | MCR cap                            |
| R0330 | MCR floor                          |
| R0340 | Combined MCR                       |
| R0350 | Absolute floor of the MCR          |
| R0400 | <b>Minimum Capital Requirement</b> |